<?xml version="1.0" encoding="utf-8"?>
<!-- Copyright ©2016 LexisNexis Univentio, The Netherlands. -->
<lexisnexis-patent-document schema-version="1.13" date-produced="20160127" file="US20150247137A1.xml" produced-by="LexisNexis-Univentio" lang="eng" date-inserted="20150903" time-inserted="021501" date-changed="20150918" time-changed="025315">
  <bibliographic-data lang="eng">
    <publication-reference publ-type="Application" publ-desc="Patent Application Publication">
      <document-id id="121140247">
        <country>US</country>
        <doc-number>20150247137</doc-number>
        <kind>A1</kind>
        <date>20150903</date>
      </document-id>
    </publication-reference>
    <application-reference appl-type="utility">
      <document-id>
        <country>US</country>
        <doc-number>14429176</doc-number>
        <date>20130918</date>
      </document-id>
    </application-reference>
    <application-series-code>14</application-series-code>
    <language-of-filing>eng</language-of-filing>
    <language-of-publication>eng</language-of-publication>
    <priority-claims date-changed="20150903">
      <priority-claim sequence="1" kind="regional">
        <country>EP</country>
        <doc-number>12184968</doc-number>
        <date>20120919</date>
      </priority-claim>
    </priority-claims>
    <dates-of-public-availability date-changed="20150910">
      <unexamined-printed-without-grant>
        <date>20150903</date>
      </unexamined-printed-without-grant>
    </dates-of-public-availability>
    <classifications-ipcr date-changed="20150910">
      <classification-ipcr sequence="1">
        <text>C12N   9/42        20060101AFI20150903BHUS        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>9</main-group>
        <subgroup>42</subgroup>
        <symbol-position>F</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20150903</date>
        </action-date>
        <generating-office>
          <country>US</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-ipcr>
    </classifications-ipcr>
    <classifications-cpc date-changed="20150910">
      <classification-cpc sequence="1">
        <text>C12N   9/2437      20130101 FI20150904BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>9</main-group>
        <subgroup>2437</subgroup>
        <symbol-position>F</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20150904</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="2">
        <text>C12N   9/2445      20130101 LI20150428BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>9</main-group>
        <subgroup>2445</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20150428</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="3">
        <text>C12Y 302/01004     20130101 LA20150903BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>12</class>
        <subclass>Y</subclass>
        <main-group>302</main-group>
        <subgroup>01004</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>A</classification-value>
        <action-date>
          <date>20150903</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
    </classifications-cpc>
    <number-of-claims calculated="yes">14</number-of-claims>
    <invention-title id="title_eng" date-changed="20150903" lang="eng" format="original">Polypeptides Having Cellulolytic Enhancing Activity and Polynucleotides Encoding Same</invention-title>
    <related-documents date-changed="20150903">
      <provisional-application>
        <document-id>
          <country>US</country>
          <doc-number>61702858</doc-number>
          <date>20120919</date>
        </document-id>
      </provisional-application>
    </related-documents>
    <parties date-changed="20150903">
      <applicants>
        <applicant sequence="1" app-type="applicant">
          <addressbook lang="eng">
            <orgname>Novozymes A/S</orgname>
            <role>03</role>
            <address>
              <city>Bagsvaerd</city>
              <country>DK</country>
            </address>
          </addressbook>
        </applicant>
      </applicants>
      <inventors>
        <inventor sequence="1" designation="us-only">
          <addressbook lang="eng">
            <last-name>Spodsberg</last-name>
            <first-name>Nkolaj</first-name>
            <address>
              <city>Bagsvaerd</city>
              <country>DK</country>
            </address>
          </addressbook>
        </inventor>
      </inventors>
    </parties>
    <pct-or-regional-filing-data>
      <document-id>
        <country>WO</country>
        <doc-number>EP13069373</doc-number>
        <date>20130918</date>
      </document-id>
    </pct-or-regional-filing-data>
    <pct-or-regional-publishing-data>
      <document-id>
        <country>WO</country>
        <doc-number>2014044708</doc-number>
        <date>20140327</date>
      </document-id>
    </pct-or-regional-publishing-data>
    <patent-family date-changed="20150903">
      <main-family family-id="164904054">
        <family-member>
          <document-id>
            <country>CN</country>
            <doc-number>104640874</doc-number>
            <kind>A</kind>
            <date>20150520</date>
          </document-id>
          <application-date>
            <date>20130918</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>US</country>
            <doc-number>20150247137</doc-number>
            <kind>A1</kind>
            <date>20150903</date>
          </document-id>
          <application-date>
            <date>20130918</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>2897973</doc-number>
            <kind>A1</kind>
            <date>20150729</date>
          </document-id>
          <application-date>
            <date>20130918</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>WO</country>
            <doc-number>2014044708</doc-number>
            <kind>A1</kind>
            <date>20140327</date>
          </document-id>
          <application-date>
            <date>20130918</date>
          </application-date>
        </family-member>
      </main-family>
      <complete-family family-id="164904051">
        <family-member>
          <document-id>
            <country>CN</country>
            <doc-number>104640874</doc-number>
            <kind>A</kind>
            <date>20150520</date>
          </document-id>
          <application-date>
            <date>20130918</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>US</country>
            <doc-number>20150247137</doc-number>
            <kind>A1</kind>
            <date>20150903</date>
          </document-id>
          <application-date>
            <date>20130918</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>2897973</doc-number>
            <kind>A1</kind>
            <date>20150729</date>
          </document-id>
          <application-date>
            <date>20130918</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>WO</country>
            <doc-number>2014044708</doc-number>
            <kind>A1</kind>
            <date>20140327</date>
          </document-id>
          <application-date>
            <date>20130918</date>
          </application-date>
        </family-member>
      </complete-family>
    </patent-family>
  </bibliographic-data>
  <abstract id="abstr_eng" date-changed="20150903" lang="eng" format="original">
    <p id="p-a-00001-en" num="0000">The present invention relates to isolated polypeptides having cellulytic enhancing activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.</p>
  </abstract>
  <legal-data date-changed="20150918">
    <legal-event sequence="1">
      <publication-date>
        <date>20150319</date>
      </publication-date>
      <event-code-1>AS</event-code-1>
      <legal-description>ASSIGNMENT</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> US  2015247137A1</docdb-publication-number>
      <docdb-application-id>444210173</docdb-application-id>
      <new-owner>NOVOZYMES A/S, DENMARK</new-owner>
      <free-text-description>ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SPODSBERG, NIKOLAJ;REEL/FRAME:035200/0216</free-text-description>
      <effective-date>
        <date>20150108</date>
      </effective-date>
    </legal-event>
  </legal-data>
  <description id="descr_eng" lang="eng" format="original" date-changed="20150903">
    <summary>
      <heading id="h-00001-en" level="1">REFERENCE TO A SEQUENCE LISTING</heading>
      <p id="p-00001-en" num="0001">This application contains a Sequence Listing in computer readable form, which is incorporated herein by reference.</p>
      <heading id="h-00002-en" level="1">BACKGROUND OF THE INVENTION</heading>
      <p id="p-00002-en" num="0002">1. Field of the Invention</p>
      <p id="p-00003-en" num="0003">The present invention relates to polypeptides having cellulolytic enhancing activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.</p>
      <p id="p-00004-en" num="0004">2. Description of the Related Art</p>
      <p id="p-00005-en" num="0005">Cellulose is a polymer of the simple sugar glucose covalently linked by beta-1,4-bonds. Many microorganisms produce enzymes that hydrolyze beta-linked glucans. These enzymes include endoglucanases, cellobiohydrolases, and beta-glucosidases. Endoglucanases digest the cellulose polymer at random locations, opening it to attack by cellobiohydrolases. Cellobiohydrolases sequentially release molecules of cellobiose from the ends of the cellulose polymer. Cellobiose is a water-soluble beta-1,4-linked dimer of glucose. Beta-glucosidases hydrolyze cellobiose to glucose.</p>
      <p id="p-00006-en" num="0006">Another class of enzymes, GH61 polypeptides having cellulolytic enhancing activity has been described in the literature These polypeptides acts together with enzymes that hydrolyze beta-linked glucans with the result that the combined activities results is a significant higher conversion of cellulosic material.</p>
      <p id="p-00007-en" num="0007">Since cellulose is present in all plants there is a considerable interest in modifying and/or degrading cellulose and due to the diversity in structure and composition of different plant materials there is also a need for a considerable diversity among enzymes for modifying and/or degrading cellulosic material.</p>
      <p id="p-00008-en" num="0008">WO 2005/074647, WO 2008/148131, and WO 2011/035027 disclose isolated GH61 polypeptides having cellulolytic enhancing activity and the polynucleotides thereof from <i>Thielavia terrestris</i>. WO 2005/074656 and WO 2010/065830 disclose isolated GH61 polypeptides having cellulolytic enhancing activity and the polynucleotides thereof from <i>Thermoascus aurantiacus</i>. WO 2007/089290 discloses an isolated GH61 polypeptide having cellulolytic enhancing activity and the polynucleotide thereof from <i>Trichoderma reesei</i>. WO 2009/085935, WO 2009/085859, WO 2009/085864, and WO 2009/085868 disclose isolated GH61 polypeptides having cellulolytic enhancing activity and the polynucleotides thereof from <i>Myceliophthora thermophila</i>. WO 2010/138754 discloses isolated GH61 polypeptides having cellulolytic enhancing activity and the polynucleotides thereof from <i>Aspergillus fumigatus</i>. WO 2011/005867 discloses isolated GH61 polypeptides having cellulolytic enhancing activity and the polynucleotides thereof from <i>Penicillium pinophilum</i>. WO 2011/039319 discloses isolated GH61 polypeptides having cellulolytic enhancing activity and the polynucleotides thereof from <i>Thermoascus </i>sp. WO 2011/041397 discloses isolated GH61 polypeptides having cellulolytic enhancing activity and the polynucleotides thereof from <i>Penicillium </i>sp. WO 2011/041504 discloses isolated GH61 polypeptides having cellulolytic enhancing activity and the polynucleotides thereof from <i>Thermoascus crustaceous</i>. WO 2008/151043 discloses methods of increasing the activity of a GH61 polypeptide having cellulolytic enhancing activity by adding a soluble activating divalent metal cation to a composition comprising the polypeptide.</p>
      <p id="p-00009-en" num="0009">There is a need in the art for new enzymes to increase efficiency and to provide cost-effective enzyme solutions for modifying and/or degrading cellulosic material.</p>
      <p id="p-00010-en" num="0010">The present invention provides GH61 polypeptides having cellulolytic enhancing activity and polynucleotides encoding the polypeptides.</p>
      <heading id="h-00003-en" level="1">SUMMARY OF THE INVENTION</heading>
      <p id="p-00011-en" num="0011">The present invention relates to isolated polypeptides having cellulolytic enhancing activity selected from the group consisting of:</p>
      <p id="p-00012-en" num="0012">(a) a polypeptide having at least 70% sequence identity to the mature polypeptide of SEQ ID NO: 2; at least 85% sequence identity to the mature polypeptide of SEQ ID NO: 4; at least 80% sequence identity to the mature polypeptide of SEQ ID NO: 6 or at least 75% sequence identity to the mature polypeptide of SEQ ID NO: 8;</p>
      <p id="p-00013-en" num="0013">(b) a polypeptide encoded by a polynucleotide that hybridizes under medium stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 (ii) the cDNA sequence thereof, or (iii) the full-length complement of (i) or (ii);</p>
      <p id="p-00014-en" num="0014">(c) a polypeptide encoded by a polynucleotide having at least 70% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1 or the cDNA sequence thereof; at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 3; at least 80% sequence identity to the mature coding sequence of SEQ ID NO:5; or at least 75% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 7;</p>
      <p id="p-00015-en" num="0015">(d) a variant of the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 comprising a substitution, deletion, and/or insertion at one or more (e.g., several) positions; and</p>
      <p id="p-00016-en" num="0016">(e) a fragment of the polypeptide of (a), (b), (c), or (d) that has cellulolytic enhancing activity.</p>
      <p id="p-00017-en" num="0017">The present invention also relates to isolated polynucleotides encoding the polypeptides of the present invention; nucleic acid constructs; recombinant expression vectors; recombinant host cells comprising the polynucleotides; and methods of producing the polypeptides.</p>
      <p id="p-00018-en" num="0018">The present invention also relates to methods of degrading cellulosic material, such as in saccharification of cellulosic materials.</p>
      <p id="p-00019-en" num="0019">The present invention also relates to a polynucleotide encoding a signal peptide comprising or consisting of amino acids 1 to 19 of SEQ ID NO: 2, amino acids 1 to 23 of SEQ ID NO: 4, amino acids 1 to 19 of SEQ ID NO: 6, or amino acids 1 to 18 of SEQ ID NO: 8 each of which is operably linked to a gene encoding a protein; nucleic acid constructs, expression vectors, and recombinant host cells comprising the polynucleotides; and methods of producing a protein.</p>
      <p id="p-00020-en" num="0020">The invention also relates to a composition comprising the polypeptide of the invention and the use thereof for degrading cellulose.</p>
      <heading id="h-00004-en" level="1">DEFINITIONS</heading>
      <p id="p-00021-en" num="0021">Cellulolytic Activity:</p>
      <p id="p-00022-en" num="0022">The term “cellulolytic activity” means a biological activity that hydrolyzes a cellulosic material. The two basic approaches for measuring cellulolytic activity include: (1) measuring the total cellulolytic activity, and (2) measuring the individual cellulolytic activities (endoglucanases, cellobiohydrolases, and beta-glucosidases) as reviewed in Zhang et al., Outlook for cellulase improvement: Screening and selection strategies, 2006<i>, Biotechnology Advances </i>24: 452-481. Total cellulolytic activity is usually measured using insoluble substrates, including Whatman No1 filter paper, microcrystalline cellulose, bacterial cellulose, algal cellulose, cotton, pretreated lignocellulose, etc. The most common total cellulolytic activity assay is the filter paper assay using Whatman No1 filter paper as the substrate. The assay was established by the International Union of Pure and Applied Chemistry (IUPAC) (Ghose, 1987, Measurement of cellulase activities, <i>Pure Appl. Chem</i>. 59: 257-68).</p>
      <p id="p-00023-en" num="0023">For purposes of the present invention, cellulolytic activity is determined by measuring the increase in hydrolysis of a cellulosic material by cellulolytic enzyme(s) under the following conditions: 1-20 mg of cellulolytic protein/g of cellulose in PCS for 3-7 days at 50-65° C. compared to a control hydrolysis without addition of cellulolytic protein. Typical conditions are 1 ml reactions, washed or unwashed PCS, 5% insoluble solids, 50 mM sodium acetate pH 5, 1 mM MnSO<sub>4</sub>, 50-65° C., 72 hours, sugar analysis by AMINEX® HPX-87H column (Bio-Rad Laboratories, Inc., Hercules, Calif., USA).</p>
      <p id="p-00024-en" num="0024">Endoglucanase:</p>
      <p id="p-00025-en" num="0025">The term “endoglucanase” means an endo-1,4-(1,3; 1,4)-beta-D-glucan 4-glucanohydrolase (E.C. 3.2.1.4), which catalyses endohydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (such as carboxymethyl cellulose and hydroxyethyl cellulose), lichenin, beta-1,4 bonds in mixed beta-1,3 glucans such as cereal beta-D-glucans or xyloglucans, and other plant material containing cellulosic components. Endoglucanase activity can be determined by measuring reduction in substrate viscosity or increase in reducing ends determined by a reducing sugar assay (Zhang et al., 2006<i>, Biotechnology Advances </i>24: 452-481). For purposes of the present invention, endoglucanase activity is determined using carboxymethyl cellulose (CMC) as substrate according to the procedure of Ghose, 1987<i>, Pure and Appl. Chem</i>. 59: 257-268, at pH 5, 40° C.</p>
      <p id="p-00026-en" num="0026">Cellobiohydrolase:</p>
      <p id="p-00027-en" num="0027">The term “cellobiohydrolase” means a 1,4-beta-D-glucan cellobiohydrolase (E.C. 3.2.1.91), which catalyzes the hydrolysis of 1,4-beta-D-glucosidic linkages in cellulose, cellooligosaccharides, or any beta-1,4-linked glucose containing polymer, releasing cellobiose from the reducing or non-reducing ends of the chain (Teeri, 1997, Crystalline cellulose degradation: New insight into the function of cellobiohydrolases, <i>Trends in Biotechnology </i>15: 160-167; Teeri et al., 1998, <i>Trichoderma reesei </i>cellobiohydrolases: why so efficient on crystalline cellulose?, <i>Biochem. Soc. Trans</i>. 26: 173-178). For purposes of the present invention, cellobiohydrolase activity is determined using a fluorescent disaccharide derivative 4-methylumbelliferyl-β-D-lactoside according to the procedures described by van Tilbeurgh et al., 1982<i>, FEBS Letters </i>149: 152-156 and van Tilbeurgh and Claeyssens, 1985<i>, FEBS Letters </i>187: 283-288, at pH 5, 40° C.</p>
      <p id="p-00028-en" num="0028">Beta-Glucosidase:</p>
      <p id="p-00029-en" num="0029">The term “beta-glucosidase” means a beta-D-glucoside glucohydrolase (E.C. 3.2.1.21), which catalyzes the hydrolysis of terminal non-reducing beta-D-glucose residues with the release of beta-D-glucose. For purposes of the present invention, beta-glucosidase activity is determined according to the basic procedure described by Venturi et al., 2002, Extracellular beta-D-glucosidase from <i>Chaetomium thermophilum </i>var. <i>coprophilum</i>: production, purification and some biochemical properties, <i>J. Basic Microbiol</i>. 42: 55-66. One unit of beta-glucosidase is defined as 1.0 μmole of p-nitrophenol produced per minute at 40° C., pH 5 from 1 mM p-nitrophenyl-beta-D-glucopyranoside as substrate in 100 mM sodium citrate containing 0.01% TWEEN® 20.</p>
      <p id="p-00030-en" num="0030">Cellulolytic Enhancing Activity:</p>
      <p id="p-00031-en" num="0031">The term “cellulolytic enhancing activity” means a biological activity catalyzed by a GH61 polypeptide that enhances the hydrolysis of a cellulosic material by enzyme having cellulolytic activity. For purposes of the present invention, cellulolytic enhancing activity is determined by measuring the increase in reducing sugars or the increase of the total of cellobiose and glucose from the hydrolysis of a cellulosic material by cellulolytic enzyme under the following conditions: 1-50 mg of total protein/g of cellulose in PCS, wherein total protein is comprised of 50-99.5% w/w cellulolytic protein and 0.5-50% w/w protein of a GH61 polypeptide having cellulolytic enhancing activity for 1-7 day at 50-65° C. compared to a control hydrolysis with equal total protein loading without cellulolytic enhancing activity (1-50 mg of cellulolytic protein/g of cellulose in PCS). In a preferred aspect, a mixture of CELLUCLAST® 1.5 L (Novozymes NS, Bagsærd, Denmark) in the presence of 3% of total protein weight <i>Aspergillus oryzae </i>beta-glucosidase (recombinantly produced in <i>Aspergillus oryzae </i>according to WO 02/095014) or 3% of total protein weight <i>Aspergillus fumigatus </i>beta-glucosidase (recombinantly produced in <i>Aspergillus oryzae </i>as described in WO 2002/095014) of cellulase protein loading is used as the source of the cellulolytic activity.</p>
      <p id="p-00032-en" num="0032">The GH61 polypeptides having cellulolytic enhancing activity enhance the hydrolysis of a cellulosic material catalyzed by enzyme having cellulolytic activity by reducing the amount of cellulolytic enzyme required to reach the same degree of hydrolysis preferably at least 1.01-fold, more preferably at least 1.05-fold, more preferably at least 1.10-fold, more preferably at least 1.25-fold, more preferably at least 1.5-fold, more preferably at least 2-fold, more preferably at least 3-fold, more preferably at least 4-fold, more preferably at least 5-fold, even more preferably at least 10-fold, and most preferably at least 20-fold.</p>
      <p id="p-00033-en" num="0033">Family 61 Glycoside Hydrolase:</p>
      <p id="p-00034-en" num="0034">The term “Family 61 glycoside hydrolase” or “Family GH61” or “GH61” means a polypeptide falling into the glycoside hydrolase Family 61 according to Henrissat B., 1991, A classification of glycosyl hydrolases based on amino-acid sequence similarities, Biochem. J. 280: 309-316, and Henrissat B., and Bairoch A., 1996, Updating the sequence-based classification of glycosyl hydrolases, <i>Biochem. J</i>. 316: 695-696.</p>
      <p id="p-00035-en" num="0035">It has recently been proposed to reclassify family GH61 as AA9 (Auxilliary Activities) by Levasseur et al. 2013, Biotechnology for Biofuels 2013 6: 41. In the present description and claims the GH61 teminology is maintained, however, the skilled person will appreciate that the invention is not in any way by the terminology used and will further appreciate that both the GH61 and the AA9 terminology can be found in the literature describing enzymes having the structural features that defines a GH61 and a AA9 polypeptide.</p>
      <p id="p-00036-en" num="0036">Xylan Degrading Activity:</p>
      <p id="p-00037-en" num="0037">The terms “xylan degrading activity” or “xylanolytic activity” mean a biological activity that hydrolyzes xylan-containing material. The two basic approaches for measuring xylanolytic activity include: (1) measuring the total xylanolytic activity, and (2) measuring the individual xylanolytic activities (endoxylanases, beta-xylosidases, arabinofuranosidases, alpha-glucuronidases, acetylxylan esterases, feruloyl esterases, and alpha-glucuronyl esterases). Recent progress in assays of xylanolytic enzymes was summarized in several publications including Biely and Puchard, Recent progress in the assays of xylanolytic enzymes, 2006<i>, Journal of the Science of Food and Agriculture </i>86(11): 1636-1647; Spanikova and Biely, 2006, Glucuronoyl esterase-Novel carbohydrate esterase produced by <i>Schizophyllum commune, FEBS Letters </i>580(19): 4597-4601; Herrmann, Vrsanska, Jurickova, Hirsch, Biely, and Kubicek, 1997, The beta-D-xylosidase of <i>Trichoderma reesei </i>is a multifunctional beta-D-xylan xylohydrolase, <i>Biochemical Journal </i>321: 375-381.</p>
      <p id="p-00038-en" num="0038">Total xylan degrading activity can be measured by determining the reducing sugars formed from various types of xylan, including, for example, oat spelt, beechwood, and larchwood xylans, or by photometric determination of dyed xylan fragments released from various covalently dyed xylans. The most common total xylanolytic activity assay is based on production of reducing sugars from polymeric 4-O-methyl glucuronoxylan as described in Bailey, Biely, Poutanen, 1992, Interlaboratory testing of methods for assay of xylanase activity, <i>Journal of Biotechnology </i>23(3): 257-270.</p>
      <p id="p-00039-en" num="0039">For purposes of the present invention, xylan degrading activity is determined by measuring the increase in hydrolysis of birchwood xylan (Sigma Chemical Co., Inc., St. Louis, Mo., USA) by xylan-degrading enzyme(s) under the following typical conditions: 1 ml reactions, 5 mg/ml substrate (total solids), 5 mg of xylanolytic protein/g of substrate, 50 mM sodium acetate pH 5, 50° C., 24 hours, sugar analysis using p-hydroxybenzoic acid hydrazide (PHBAH) assay as described by Lever, 1972, A new reaction for colorimetric determination of carbohydrates, <i>Anal. Biochem </i>47: 273-279.</p>
      <p id="p-00040-en" num="0040">Xylanase:</p>
      <p id="p-00041-en" num="0041">The term “xylanase” means a 1,4-beta-D-xylan-xylohydrolase (E.C. 3.2.1.8) that catalyzes the endo-hydrolysis of 1,4-beta-D-xylosidic linkages in xylans. For purposes of the present invention, xylanase activity is determined using birchwood xylan as substrate. One unit of xylanase is defined as 1.0 μmole of reducing sugar (measured in glucose equivalents as described by Lever, 1972, A new reaction for colorimetric determination of carbohydrates, <i>Anal. Biochem </i>47: 273-279) produced per minute during the initial period of hydrolysis at 50° C., pH 5 from 2 g of birchwood xylan per liter as substrate in 50 mM sodium acetate containing 0.01% TWEEN® 20.</p>
      <p id="p-00042-en" num="0042">Beta-Xylosidase:</p>
      <p id="p-00043-en" num="0043">The term “beta-xylosidase” means a beta-D-xyloside xylohydrolase (E.C. 3.2.1.37) that catalyzes the exo-hydrolysis of short beta (1-*4)-xylooligosaccharides, to remove successive D-xylose residues from the non-reducing termini. For purposes of the present invention, one unit of beta-xylosidase is defined as 1.0 μmole of p-nitrophenol produced per minute at 40° C., pH 5 from 1 mM p-nitrophenyl-beta-D-xyloside as substrate in 100 mM sodium citrate containing 0.01% TWEEN® 20.</p>
      <p id="p-00044-en" num="0044">Acetylxylan Esterase:</p>
      <p id="p-00045-en" num="0045">The term “acetylxylan esterase” means a carboxylesterase (EC 3.1.1.72) that catalyses the hydrolysis of acetyl groups from polymeric xylan, acetylated xylose, acetylated glucose, alpha-napthyl acetate, and p-nitrophenyl acetate. For purposes of the present invention, acetylxylan esterase activity is determined using 0.5 mM p-nitrophenylacetate as substrate in 50 mM sodium acetate pH 5.0 containing 0.01% TWEEN™ 20. One unit of acetylxylan esterase is defined as the amount of enzyme capable of releasing 1 μmole of p-nitrophenolate anion per minute at pH 5, 25° C.</p>
      <p id="p-00046-en" num="0046">Feruloyl Esterase:</p>
      <p id="p-00047-en" num="0047">The term “feruloyl esterase” means a 4-hydroxy-3-methoxycinnamoyl-sugar hydrolase (EC 3.1.1.73) that catalyzes the hydrolysis of the 4-hydroxy-3-methoxycinnamoyl (feruloyl) group from an esterified sugar, which is usually arabinose in “natural” substrates, to produce ferulate (4-hydroxy-3-methoxycinnamate). Feruloyl esterase is also known as ferulic acid esterase, hydroxycinnamoyl esterase, FAE-III, cinnamoyl ester hydrolase, FAEA, cinnAE, FAE-I, or FAE-II. For purposes of the present invention, feruloyl esterase activity is determined using 0.5 mM p-nitrophenylferulate as substrate in 50 mM sodium acetate pH 5.0. One unit of feruloyl esterase equals the amount of enzyme capable of releasing 1 μmole of p-nitrophenolate anion per minute at pH 5, 25° C.</p>
      <p id="p-00048-en" num="0048">Alpha-Glucuronidase:</p>
      <p id="p-00049-en" num="0049">The term “alpha-glucuronidase” means an alpha-D-glucosiduronate glucuronohydrolase (EC 3.2.1.139) that catalyzes the hydrolysis of an alpha-D-glucuronoside to D-glucuronate and an alcohol. For purposes of the present invention, alpha-glucuronidase activity is determined according to de Vries, 1998<i>, J. Bacteriol</i>. 180: 243-249. One unit of alpha-glucuronidase equals the amount of enzyme capable of releasing 1 μmole of glucuronic or 4-O-methylglucuronic acid per minute at pH 5, 40° C.</p>
      <p id="p-00050-en" num="0050">Alpha-L-Arabinofuranosidase:</p>
      <p id="p-00051-en" num="0051">The term “alpha-L-arabinofuranosidase” means an alpha-L-arabinofuranoside arabinofuranohydrolase (EC 3.2.1.55) that catalyzes the hydrolysis of terminal non-reducing alpha-L-arabinofuranoside residues in alpha-L-arabinosides. The enzyme acts on alpha-L-arabinofuranosides, alpha-L-arabinans containing (1,3)- and/or (1,5)-linkages, arabinoxylans, and arabinogalactans. Alpha-L-arabinofuranosidase is also known as arabinosidase, alpha-arabinosidase, alpha-L-arabinosidase, alpha-arabinofuranosidase, polysaccharide alpha-L-arabinofuranosidase, alpha-L-arabinofuranoside hydrolase, L-arabinosidase, or alpha-L-arabinanase. For purposes of the present invention, alpha-L-arabinofuranosidase activity is determined using 5 mg of medium viscosity wheat arabinoxylan (Megazyme International Ireland, Ltd., Bray, Co. Wicklow, Ireland) per ml of 100 mM sodium acetate pH 5 in a total volume of 200 μl for 30 minutes at 40° C. followed by arabinose analysis by AMINEX® HPX-87H column chromatography (Bio-Rad Laboratories, Inc., Hercules, Calif., USA).</p>
      <p id="p-00052-en" num="0052">Cellulosic Material:</p>
      <p id="p-00053-en" num="0053">The cellulosic material can be any material containing cellulose. The predominant polysaccharide in the primary cell wall of biomass is cellulose, the second most abundant is hemicellulose, and the third is pectin. The secondary cell wall, produced after the cell has stopped growing, also contains polysaccharides and is strengthened by polymeric lignin covalently cross-linked to hemicellulose. Cellulose is a homopolymer of anhydrocellobiose and thus a linear beta-(1-4)-D-glucan, while hemicelluloses include a variety of compounds, such as xylans, xyloglucans, arabinoxylans, and mannans in complex branched structures with a spectrum of substituents. Although generally polymorphous, cellulose is found in plant tissue primarily as an insoluble crystalline matrix of parallel glucan chains. Hemicelluloses usually hydrogen bond to cellulose, as well as to other hemicelluloses, which help stabilize the cell wall matrix.</p>
      <p id="p-00054-en" num="0054">Cellulose is generally found, for example, in the stems, leaves, hulls, husks, and cobs of plants or leaves, branches, and wood of trees. The cellulosic material can be, but is not limited to, herbaceous material, agricultural residue, forestry residue, municipal solid waste, waste paper, and pulp and paper mill residue (see, for example, Wiselogel et al., 1995, in Handbook on Bioethanol (Charles E. Wyman, editor), pp. 105-118, Taylor &amp; Francis, Washington D.C.; Wyman, 1994<i>, Bioresource Technology </i>50: 3-16; Lynd, 1990<i>, Applied Biochemistry and Biotechnology </i>24/25: 695-719; Mosier et al., 1999, Recent Progress in Bioconversion of Lignocellulosics, in <i>Advances in Biochemical Engineering/Biotechnology</i>, T. Scheper, managing editor, Volume 65, pp. 23-40, Springer-Verlag, New York). It is understood herein that the cellulose may be in the form of lignocellulose, a plant cell wall material containing lignin, cellulose, and hemicellulose in a mixed matrix. In a preferred aspect, the cellulosic material is lignocellulose.</p>
      <p id="p-00055-en" num="0055">In one aspect, the cellulosic material is herbaceous material. In another aspect, the cellulosic material is agricultural residue. In another aspect, the cellulosic material is forestry residue. In another aspect, the cellulosic material is municipal solid waste. In another aspect, the cellulosic material is waste paper. In another aspect, the cellulosic material is pulp and paper mill residue.</p>
      <p id="p-00056-en" num="0056">In another aspect, the cellulosic material is corn stover. In another aspect, the cellulosic material is corn fiber. In another aspect, the cellulosic material is corn cob. In another aspect, the cellulosic material is orange peel. In another aspect, the cellulosic material is rice straw. In another aspect, the cellulosic material is wheat straw. In another aspect, the cellulosic material is switch grass. In another aspect, the cellulosic material is miscanthus. In another aspect, the cellulosic material is bagasse.</p>
      <p id="p-00057-en" num="0057">In another aspect, the cellulosic material is microcrystalline cellulose. In another aspect, the cellulosic material is bacterial cellulose. In another aspect, the cellulosic material is algal cellulose. In another aspect, the cellulosic material is cotton linter. In another aspect, the cellulosic material is amorphous phosphoric-acid treated cellulose. In another aspect, the cellulosic material is filter paper.</p>
      <p id="p-00058-en" num="0058">The cellulosic material may be used as is or may be subjected to pretreatment, using conventional methods known in the art, as described herein. In a preferred aspect, the cellulosic material is pretreated.</p>
      <p id="p-00059-en" num="0059">Pretreated Corn Stover:</p>
      <p id="p-00060-en" num="0060">The term “PCS” or “Pretreated Corn Stover” means a cellulosic material derived from corn stover by treatment with heat and dilute sulfuric acid.</p>
      <p id="p-00061-en" num="0061">Xylan-Containing Material:</p>
      <p id="p-00062-en" num="0062">The term “xylan-containing material” means any material comprising a plant cell wall polysaccharide containing a backbone of beta-(1-4)-linked xylose residues. Xylans of terrestrial plants are heteropolymers possessing a beta-(1-4)-D-xylopyranose backbone, which is branched by short carbohydrate chains. They comprise D-glucuronic acid or its 4-O-methyl ether, L-arabinose, and/or various oligosaccharides, composed of D-xylose, L-arabinose, D- or L-galactose, and D-glucose. Xylan-type polysaccharides can be divided into homoxylans and heteroxylans, which include glucuronoxylans, (arabino)glucuronoxylans, (glucurono)arabinoxylans, arabinoxylans, and complex heteroxylans. See, for example, Ebringerova et al., 2005<i>, Adv. Polym. Sci</i>. 186: 1-67.</p>
      <p id="p-00063-en" num="0063">In the methods of the present invention, any material containing xylan may be used. In a preferred aspect, the xylan-containing material is lignocellulose.</p>
      <p id="p-00064-en" num="0064">Allelic Variant:</p>
      <p id="p-00065-en" num="0065">The term “allelic variant” means any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.</p>
      <p id="p-00066-en" num="0066">Carbohydrate Binding Domain:</p>
      <p id="p-00067-en" num="0067">The term “carbohydrate binding domain” means the region of a polypeptide such as an enzyme; that mediates binding of the polypeptide to a carbohydrate substrate, where to the binding domain has affinity. The carbohydrate binding domain is typically found either at the N-terminal or at the C-terminal extremity of a polypeptide.</p>
      <p id="p-00068-en" num="0068">Catalytic Domain:</p>
      <p id="p-00069-en" num="0069">The term “catalytic domain” means the region of an enzyme containing the catalytic machinery of the enzyme.</p>
      <p id="p-00070-en" num="0070">cDNA:</p>
      <p id="p-00071-en" num="0071">The term “cDNA” means a DNA molecule that can be prepared by reverse transcription from a mature, spliced, mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA. The initial, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature spliced mRNA.</p>
      <p id="p-00072-en" num="0072">Coding Sequence:</p>
      <p id="p-00073-en" num="0073">The term “coding sequence” means a polynucleotide, which directly specifies the amino acid sequence of a polypeptide. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon such as ATG, GTG, or TTG and ends with a stop codon such as TAA, TAG, or TGA. The coding sequence may be a genomic DNA, cDNA, synthetic DNA, or a combination thereof.</p>
      <p id="p-00074-en" num="0074">Control Sequences:</p>
      <p id="p-00075-en" num="0075">The term “control sequences” means nucleic acid sequences necessary for expression of a polynucleotide encoding a mature polypeptide of the present invention. Each control sequence may be native (i.e., from the same gene) or foreign (i.e., from a different gene) to the polynucleotide encoding the polypeptide or native or foreign to each other. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the polynucleotide encoding a polypeptide.</p>
      <p id="p-00076-en" num="0076">Expression:</p>
      <p id="p-00077-en" num="0077">The term “expression” includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.</p>
      <p id="p-00078-en" num="0078">Expression Vector:</p>
      <p id="p-00079-en" num="0079">The term “expression vector” means a linear or circular DNA molecule that comprises a polynucleotide encoding a polypeptide and is operably linked to control sequences that provide for its expression.</p>
      <p id="p-00080-en" num="0080">Fragment:</p>
      <p id="p-00081-en" num="0081">The term “fragment” means a polypeptide or a catalytic or carbohydrate binding domain having one or more (e.g., several) amino acids absent from the amino and/or carboxyl terminus of a mature polypeptide or domain; wherein the fragment has cellulolytic enhancing or carbohydrate binding activity. In one aspect, a fragment contains at least 180 amino acid residues (e.g., amino acids 20 to 200 of SEQ ID NO: 2), at least 200 amino acid residues (e.g., amino acids 20 to 220 of SEQ ID NO: 2), or at least 250 amino acid residues (e.g., amino acids 20 to 270 of SEQ ID NO: 2); at least 230 amino acid residues (e.g. amino acids 24 to 250 of SEQ ID NO: 4), at least 250 amino acid residues (e.g. amino acids 24 to 274 of SEQ ID NO: 4), or at least 275 amino acid residues (e.g. amino acids 24 to 299 of SEQ ID NO: 4); at least 200 amino acid residues (e.g. amino acids 20 to 220 of SEQ ID NO:6) or at least 210 amino acid residues (e.g. amino acids 19 to 239 of SEQ ID NO: 6); at least 200 amino acid residues (e.g. amino acids 25 to 225 of SEQ ID NO: 8); at least 250 amino acid residues (e.g. amino acids 25 to 275 of SEQ ID NO: 8) or at least 275 amino acid residues (e.g. amino acids 25 to 300 of SEQ ID NO: 8).</p>
      <p id="p-00082-en" num="0082">High Stringency Conditions:</p>
      <p id="p-00083-en" num="0083">The term “high stringency conditions” means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2×SSC, 0.2% SDS at 65° C.</p>
      <p id="p-00084-en" num="0084">Host Cell:</p>
      <p id="p-00085-en" num="0085">The term “host cell” means any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term “host cell” encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.</p>
      <p id="p-00086-en" num="0086">Isolated:</p>
      <p id="p-00087-en" num="0087">The term “isolated” means a substance in a form or environment that does not occur in nature. Non-limiting examples of isolated substances include (1) any non-naturally occurring substance, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, that is at least partially removed from one or more or all of the naturally occurring constituents with which it is associated in nature; (3) any substance modified by the hand of man relative to that substance found in nature; or (4) any substance modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., multiple copies of a gene encoding the substance; use of a stronger promoter than the promoter naturally associated with the gene encoding the substance). An isolated substance may be present in a fermentation broth sample.</p>
      <p id="p-00088-en" num="0088">Low Stringency Conditions:</p>
      <p id="p-00089-en" num="0089">The term “low stringency conditions” means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 25% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2×SSC, 0.2% SDS at 50° C.</p>
      <p id="p-00090-en" num="0090">Mature Polypeptide:</p>
      <p id="p-00091-en" num="0091">The term “mature polypeptide” means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc. In one aspect, the mature polypeptide is amino acids 20 to 299 of SEQ ID NO: 2, amino acids 24 to 321 of SEQ ID NO: 4, amino acids 20 to 240 of SEQ ID NO: 6 or amino acids 19 to 355 of SEQ ID NO: 8 based on the SignalP program (Nielsen et al., 1997<i>, Protein Engineering </i>10: 1-6)] that predicts amino acids 1 to 19 of SEQ ID NO: 2, amino acids 1 to 23 of SEQ ID NO: 4, amino acids 1 to 19 of SEQ ID NO: 6 or amino acids 1 to 18 of SEQ ID NO: 8 are a signal peptide. It is known in the art that a host cell may produce a mixture of two of more different mature polypeptides (i.e., with a different C-terminal and/or N-terminal amino acid) expressed by the same polynucleotide.</p>
      <p id="p-00092-en" num="0092">Mature Polypeptide Coding Sequence:</p>
      <p id="p-00093-en" num="0093">The term “mature polypeptide coding sequence” means a polynucleotide that encodes a mature polypeptide having cellulolytic enhancing activity. In one aspect, the mature polypeptide coding sequence is nucleotides 158 to 1382 of SEQ ID NO: 1, nucleotides 170 to 1332 of SEQ ID NO: 3, nucleotides 336 to 1580 of SEQ ID NO: 5 or nucleotides 155 to 1404 of SEQ ID NO: 7; or the cDNA sequences thereof based on the SignalP program (Nielsen et al., 1997, supra)] that predicts nucleotides 101 to 157 of SEQ ID NO: 1, nucleotides 101 to 169 of SEQ ID NO: 3, nucleotides 279 to 335 of SEQ ID NO: 5 or nucleotides 101 to 154 of SEQ ID NO: 7 encode a signal peptide.</p>
      <p id="p-00094-en" num="0094">Medium Stringency Conditions:</p>
      <p id="p-00095-en" num="0095">The term “medium stringency conditions” means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 35% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2×SSC, 0.2% SDS at 55° C.</p>
      <p id="p-00096-en" num="0096">Medium-High Stringency Conditions:</p>
      <p id="p-00097-en" num="0097">The term “medium-high stringency conditions” means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and either 35% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2×SSC, 0.2% SDS at 60° C.</p>
      <p id="p-00098-en" num="0098">Nucleic Acid Construct:</p>
      <p id="p-00099-en" num="0099">The term “nucleic acid construct” means a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, which comprises one or more control sequences.</p>
      <p id="p-00100-en" num="0100">Operably Linked:</p>
      <p id="p-00101-en" num="0101">The term “operably linked” means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs expression of the coding sequence.</p>
      <p id="p-00102-en" num="0102">Sequence Identity:</p>
      <p id="p-00103-en" num="0103">The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter “sequence identity”.</p>
      <p id="p-00104-en" num="0104">For purposes of the present invention, the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970<i>, J. Mol. Biol</i>. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000<i>, Trends Genet</i>. 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle labeled “longest identity” (obtained using the—nobrief option) is used as the percent identity and is calculated as follows:</p>
      <p id="p-00105-en" num="0000">[in-line-formulae](Identical Residues×100)/(Length of Alignment−Total Number of Gaps in Alignment)[/in-line-formulae]</p>
      <p id="p-00106-en" num="0105">For purposes of the present invention, the sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labeled “longest identity” (obtained using the—nobrief option) is used as the percent identity and is calculated as follows:</p>
      <p id="p-00107-en" num="0000">[in-line-formulae](Identical Deoxyribonucleotides×100)/(Length of Alignment−Total Number of Gaps in Alignment)[/in-line-formulae]</p>
      <p id="p-00108-en" num="0106">Subsequence:</p>
      <p id="p-00109-en" num="0107">The term “subsequence” means a polynucleotide having one or more (e.g., several) nucleotides absent from the 5′ and/or 3′ end of a mature polypeptide coding sequence; wherein the subsequence encodes a fragment having cellulolytic enhancing activity. In one aspect, a subsequence contains at least 800 nucleotides (e.g., nucleotides 158 to 1025 of SEQ ID NO: 1), at least 900 nucleotides (e.g., nucleotides 158 to 1085 of SEQ ID NO: 1), or at least 1050 nucleotides (e.g., nucleotides 158 to 1235 of SEQ ID NO: 1); at least 800 nucleotides (e.g., nucleotides 172 to 1041 of SEQ ID NO: 3), at least 900 nucleotides (e.g., nucleotides 172 to 1113 of SEQ ID NO: 3), or at least 1100 nucleotides (e.g., nucleotides 172 to 1188 of SEQ ID NO: 3); at least 1100 nucleotides (e.g., nucleotides 336 to 1445 of SEQ ID NO: 5), or at least 1250 nucleotides (e.g., nucleotides 333 to 1577 of SEQ ID NO: 5); at least 800 nucleotides (e.g., nucleotides 173 to 1014 of SEQ ID NO: 7), at least 900 nucleotides (e.g., nucleotides 173 to 1164 of SEQ ID NO: 7), or at least 1050 nucleotides (e.g., nucleotides 173 to 1239 of SEQ ID NO: 7).</p>
      <p id="p-00110-en" num="0108">Variant:</p>
      <p id="p-00111-en" num="0109">The term “variant” means a polypeptide having cellulolytic enhancing activity comprising an alteration, i.e., a substitution, insertion, and/or deletion, at one or more (e.g., several) positions. A substitution means replacement of the amino acid occupying a position with a different amino acid; a deletion means removal of the amino acid occupying a position; and an insertion means adding one or more (e.g. several) amino acids, e.g. 1-5 amino acids adjacent to and immediately following the amino acid occupying a position.</p>
      <p id="p-00112-en" num="0110">Very High Stringency Conditions:</p>
      <p id="p-00113-en" num="0111">The term “very high stringency conditions” means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2×SSC, 0.2% SDS at 70° C.</p>
      <p id="p-00114-en" num="0112">Very Low Stringency Conditions:</p>
      <p id="p-00115-en" num="0113">The term “very low stringency conditions” means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 25% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2×SSC, 0.2% SDS at 45° C.</p>
    </summary>
    <detailed-desc>
      <heading id="h-00005-en" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading>
      <heading id="h-00006-en" level="1">Polypeptides Having Cellulolytic Enhancing Activity</heading>
      <p id="p-00116-en" num="0114">In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 2 of at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, which have cellulytic enhancing activity. In one aspect, the polypeptides differ by no more than 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9, from the mature polypeptide of SEQ ID NO: 2.</p>
      <p id="p-00117-en" num="0115">A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 2 or an allelic variant thereof; or is a fragment thereof having cellulolytic enhancing activity. In another aspect, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 2. In another aspect, the polypeptide comprises or consists of amino acids 20 to 299 of SEQ ID NO: 2.</p>
      <p id="p-00118-en" num="0116">In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, which have cellulolytic enhancing activity. In one aspect, the polypeptides differ by no more than 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9, from the mature polypeptide of SEQ ID NO: 4.</p>
      <p id="p-00119-en" num="0117">A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 4 or an allelic variant thereof; or is a fragment thereof having cellulolytic enhancing activity. In another aspect, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 4. In another aspect, the polypeptide comprises or consists of amino acids 24 to 321 of SEQ ID NO: 4.</p>
      <p id="p-00120-en" num="0118">In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 6 of at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, which have cellulytic enhancing activity. In one aspect, the polypeptides differ by no more than 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9, from the mature polypeptide of SEQ ID NO: 6.</p>
      <p id="p-00121-en" num="0119">A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 6 or an allelic variant thereof; or is a fragment thereof having cellulytic enhancing activity. In another aspect, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 6. In another aspect, the polypeptide comprises or consists of amino acids 20 to 240 of SEQ ID NO: 6.</p>
      <p id="p-00122-en" num="0120">In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, which have cellulolytic enhancing activity. In one aspect, the polypeptides differ by no more than 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9, from the mature polypeptide of SEQ ID NO: 8.</p>
      <p id="p-00123-en" num="0121">A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 8 or an allelic variant thereof; or is a fragment thereof having cellulolytic enhancing activity. In another aspect, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 8. In another aspect, the polypeptide comprises or consists of amino acids 19 to 355 of SEQ ID NO: 8.</p>
      <p id="p-00124-en" num="0122">In another embodiment, the present invention relates to an isolated polypeptide having cellulolytic enhancing activity encoded by a polynucleotide that hybridizes under medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO:7, (ii) the cDNA sequences thereof, or (iii) the full-length complement of (i) or (ii) (Sambrook et al., 1989<i>, Molecular Cloning, A Laboratory Manual</i>, 2d edition, Cold Spring Harbor, New York).</p>
      <p id="p-00125-en" num="0123">The polynucleotide of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or a subsequence thereof, as well as the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 or a fragment thereof, may be used to design nucleic acid probes to identify and clone DNA encoding polypeptides having cellulolytic enhancing activity from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic DNA or cDNA of a cell of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, e.g., at least 25, at least 35, or at least 70 nucleotides in length. Preferably, the nucleic acid probe is at least 100 nucleotides in length, e.g., at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, or at least 900 nucleotides in length. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with <sup>32</sup>P, <sup>3</sup>H, <sup>35</sup>S, biotin, or avidin). Such probes are encompassed by the present invention.</p>
      <p id="p-00126-en" num="0124">A genomic DNA or cDNA library prepared from such other strains may be screened for DNA that hybridizes with the probes described above and encodes a polypeptide having cellulolytic enhancing activity. Genomic or other DNA from such other strains may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA that hybridizes with SEQ ID NO: 1 or a subsequence thereof, the carrier material is used in a Southern blot.</p>
      <p id="p-00127-en" num="0125">For purposes of the present invention, hybridization indicates that the polynucleotide hybridizes to a labeled nucleic acid probe corresponding to (i) SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7; (ii) the mature polypeptide coding sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 (iii) the cDNA sequences thereof; (iv) the full-length complement thereof; or (v) a subsequence thereof; under very low to very high stringency conditions. Molecules to which the nucleic acid probe hybridizes under these conditions can be detected using, for example, X-ray film or any other detection means known in the art.</p>
      <p id="p-00128-en" num="0126">In another embodiment, the present invention relates to an isolated polypeptide having cellulolytic enhancing activity encoded by a polynucleotide having a sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1 or the cDNA sequence thereof of at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%.</p>
      <p id="p-00129-en" num="0127">In another embodiment, the present invention relates to an isolated polypeptide having cellulolytic enhancing activity encoded by a polynucleotide having a sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 3 or the cDNA sequence thereof of at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%.</p>
      <p id="p-00130-en" num="0128">In another embodiment, the present invention relates to an isolated polypeptide having cellulolytic enhancing activity encoded by a polynucleotide having a sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 5 or the cDNA sequence thereof of at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%.</p>
      <p id="p-00131-en" num="0129">In another embodiment, the present invention relates to an isolated polypeptide having cellulolytic enhancing activity encoded by a polynucleotide having a sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 7 or the cDNA sequence thereof of at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%.</p>
      <p id="p-00132-en" num="0130">In another embodiment, the present invention relates to variants of the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 comprising a substitution, deletion, and/or insertion at one or more (e.g., several) positions. In an embodiment, the number of amino acid substitutions, deletions and/or insertions introduced into the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 is not more than 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8 or 9. The amino acid changes may be of a minor nature, that is conservative amino acid substitutions or insertions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of 1-30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.</p>
      <p id="p-00133-en" num="0131">Examples of conservative substitutions are within the groups of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions that do not generally alter specific activity are known in the art and are described, for example, by H. Neurath and R. L. Hill, 1979<i>, In, The Proteins</i>, Academic Press, New York. Common substitutions are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, AlaNal, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly.</p>
      <p id="p-00134-en" num="0132">Alternatively, the amino acid changes are of such a nature that the physico-chemical properties of the polypeptides are altered. For example, amino acid changes may improve the thermal stability of the polypeptide, alter the substrate specificity, change the pH optimum, and the like.</p>
      <p id="p-00135-en" num="0133">Essential amino acids in a polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989, <i>Science </i>244: 1081-1085). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for cellulase enhancing activity to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., 1996<i>, J. Biol. Chem. </i>271: 4699-4708. The active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., 1992, <i>Science </i>255: 306-312; Smith et al., 1992<i>, J. Mol. Biol. </i>224: 899-904; Wlodaver et al., 1992, <i>FEBS Lett. </i>309: 59-64. The identity of essential amino acids can also be inferred from an alignment with a related polypeptide.</p>
      <p id="p-00136-en" num="0134">Single or multiple amino acid substitutions, deletions, and/or insertions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988<i>, Science </i>241: 53-57; Bowie and Sauer, 1989<i>, Proc. Natl. Acad. Sci. USA </i>86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can be used include error-prone PCR, phage display (e.g., Lowman et al., 1991<i>, Biochemistry </i>30: 10832-10837; U.S. Pat. No. 5,223,409; WO 92/06204), and region-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145; Ner et al., 1988<i>, DNA </i>7: 127).</p>
      <p id="p-00137-en" num="0135">Mutagenesis/shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells (Ness et al., 1999, <i>Nature Biotechnology </i>17: 893-896). Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide.</p>
      <p id="p-00138-en" num="0136">The polypeptide may be a hybrid polypeptide in which a region of one polypeptide is fused at the N-terminus or the C-terminus of a region of another polypeptide.</p>
      <p id="p-00139-en" num="0137">The polypeptide may be a fusion polypeptide or cleavable fusion polypeptide in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide of the present invention. A fusion polypeptide is produced by fusing a polynucleotide encoding another polypeptide to a polynucleotide of the present invention. Techniques for producing fusion polypeptides are known in the art, and include ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fusion polypeptide is under control of the same promoter(s) and terminator. Fusion polypeptides may also be constructed using intein technology in which fusion polypeptides are created post-translationally (Cooper et al., 1993, <i>EMBO J. </i>12: 2575-2583; Dawson et al., 1994, <i>Science </i>266: 776-779).</p>
      <p id="p-00140-en" num="0138">A fusion polypeptide can further comprise a cleavage site between the two polypeptides. Upon secretion of the fusion protein, the site is cleaved releasing the two polypeptides. Examples of cleavage sites include, but are not limited to, the sites disclosed in Martin et al., 2003, <i>J. Ind. Microbiol. Biotechnol. </i>3: 568-576; Svetina et al., 2000, <i>J. Biotechnol. </i>76: 245-251; Rasmussen-Wilson et al., 1997, <i>Appl. Environ. Microbiol. </i>63: 3488-3493; Ward et al., 1995, <i>Biotechnology </i>13: 498-503; and Contreras et al., 1991, <i>Biotechnology </i>9: 378-381; Eaton et al., 1986<i>, Biochemistry </i>25: 505-512; Collins-Racie et al., 1995, <i>Biotechnology </i>13: 982-987; Carter et al., 1989, <i>Proteins: Structure, Function, and Genetics </i>6: 240-248; and Stevens, 2003, <i>Drug Discovery World </i>4: 35-48.</p>
      <heading id="h-00007-en" level="2">Sources of Polypeptides Having Cellulolytic Enhancing Activity</heading>
      <p id="p-00141-en" num="0139">A polypeptide having cellulolytic enhancing activity of the present invention may be obtained from microorganisms of any genus. For purposes of the present invention, the term “obtained from” as used herein in connection with a given source shall mean that the polypeptide encoded by a polynucleotide is produced by the source or by a strain in which the polynucleotide from the source has been inserted. In one aspect, the polypeptide obtained from a given source is secreted extracellularly.</p>
      <p id="p-00142-en" num="0140">The polypeptide may be a fungal polypeptide. For example, the polypeptide may be a yeast polypeptide such as a <i>Candida, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces</i>, or <i>Yarrowia </i>polypeptide; or a filamentous fungal polypeptide such as an <i>Acremonium, Agaricus, Alternaria, Aspergillus, Aureobasidium, Botryosphaeria, Ceriporiopsis, Chaetomidium, Chrysosporium, Claviceps, Cochliobolus, Coprinopsis, Coptotermes, Corynascus, Cryphonectria, Cryptococcus, Diplodia, Exidia, Filibasidium, Fusarium, Gibberella, Holomastigotoides, Humicola, Irpex, Lentinula, Lentinus, Leptospaeria, Magnaporthe, Melanocarpus, Meripilus, Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Piromyces, Poitrasia, Pseudoplectania, Pseudotrichonympha, Rhizomucor, Schizophyllum, Scytalidium, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma, Trichophaea, Verticillium, Volvariella</i>, or <i>Xylaria </i>polypeptide.</p>
      <p id="p-00143-en" num="0141">In another aspect, the polypeptide is a <i>Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis</i>, or <i>Saccharomyces oviformis </i>polypeptide.</p>
      <p id="p-00144-en" num="0142">In another aspect, the polypeptide is an <i>Acremonium cellulolyticus, Aspergillus aculeatus, Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola grisea, Humicola insolens, Humicola lanuginosa, Irpex lacteus, Lentinus similis, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium funiculosum, Penicillium purpurogenum, Phanerochaete chrysosporium, Thielavia achromatica, Thielavia albomyces, Thielavia albopilosa, Thielavia australeinsis, Thielavia fimeti, Thielavia microspora, Thielavia ovispora, Thielavia peruviana, Thielavia setosa, Thielavia spededonium, Thielavia subthermophila, Thielavia terrestris, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei</i>, or <i>Trichoderma viride </i>polypeptide.</p>
      <p id="p-00145-en" num="0143">In another aspect, the polypeptide is a <i>Lentinus similis </i>polypeptide. It will be understood that for the aforementioned species, the invention encompasses both the perfect and imperfect states, and other taxonomic equivalents, e.g., anamorphs, regardless of the species name by which they are known. Those skilled in the art will readily recognize the identity of appropriate equivalents.</p>
      <p id="p-00146-en" num="0144">Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).</p>
      <p id="p-00147-en" num="0145">The polypeptide may be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) or DNA samples obtained directly from natural materials (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms and DNA directly from natural habitats are well known in the art. A polynucleotide encoding the polypeptide may then be obtained by similarly screening a genomic DNA or cDNA library of another microorganism or mixed DNA sample. Once a polynucleotide encoding a polypeptide has been detected with the probe(s), the polynucleotide can be isolated or cloned by utilizing techniques that are known to those of ordinary skill in the art (see, e.g., Sambrook et al., 1989, supra).</p>
      <heading id="h-00008-en" level="2">Polynucleotides</heading>
      <p id="p-00148-en" num="0146">The present invention also relates to isolated polynucleotides encoding a polypeptide of the present invention, as described herein.</p>
      <p id="p-00149-en" num="0147">The techniques used to isolate or clone a polynucleotide are known in the art and include isolation from genomic DNA or cDNA, or a combination thereof. The cloning of the polynucleotides from genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, <i>PCR: A Guide to Methods and Application</i>, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligation activated transcription (LAT) and polynucleotide-based amplification (NASBA) may be used. The polynucleotides may be cloned from a strain of <i>Lentinus similis</i>, or a related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the polynucleotide.</p>
      <p id="p-00150-en" num="0148">Modification of a polynucleotide encoding a polypeptide of the present invention may be necessary for synthesizing polypeptides substantially similar to the polypeptide. The term “substantially similar” to the polypeptide refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the polypeptide isolated from its native source, e.g., variants that differ in specific activity, thermostability, pH optimum, or the like. The variants may be constructed on the basis of the polynucleotide presented as the mature polypeptide coding sequence of SEQ ID NO: 1 or the cDNA sequence thereof, the mature polypeptide coding sequence of SEQ ID NO: 3 or the cDNA sequence thereof, the mature polypeptide coding sequence of SEQ ID NO: 5 or the cDNA sequence thereof, the mature polypeptide coding sequence of SEQ ID NO: 7 or the cDNA sequence thereof, e.g., a subsequence thereof, and/or by introduction of nucleotide substitutions that do not result in a change in the amino acid sequence of the polypeptide, but which correspond to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions that may give rise to a different amino acid sequence. For a general description of nucleotide substitution, see, e.g., Ford et al., 1991, <i>Protein Expression and Purification </i>2: 95-107.</p>
      <heading id="h-00009-en" level="2">Nucleic Acid Constructs</heading>
      <p id="p-00151-en" num="0149">The present invention also relates to nucleic acid constructs comprising a polynucleotide of the present invention operably linked to one or more control sequences that direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.</p>
      <p id="p-00152-en" num="0150">A polynucleotide may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotides utilizing recombinant DNA methods are well known in the art.</p>
      <p id="p-00153-en" num="0151">The control sequence may be a promoter, a polynucleotide that is recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the present invention. The promoter contains transcriptional control sequences that mediate the expression of the polypeptide. The promoter may be any polynucleotide that shows transcriptional activity in the host cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.</p>
      <p id="p-00154-en" num="0152">Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a bacterial host cell are the promoters obtained from the <i>Bacillus amyloliquefaciens </i>alpha-amylase gene (amyQ), <i>Bacillus licheniformis </i>alpha-amylase gene (amyL), <i>Bacillus licheniformis </i>penicillinase gene (penP), <i>Bacillus stearothermophilus </i>maltogenic amylase gene (amyM), <i>Bacillus subtilis </i>levansucrase gene (sacB), <i>Bacillus subtilis </i>xylA and xylB genes, <i>Bacillus thuringiensis </i>cryIIIA gene (Agaisse and Lereclus, 1994, Molecular Microbiology 13: 97-107), <i>E. coli </i>lac operon, <i>E. coli </i>trc promoter (Egon et al., 1988, Gene 69: 301-315), <i>Streptomyces coelicolor </i>agarase gene (dagA), and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978<i>, Proc. Natl. Acad. Sci. USA </i>75: 3727-3731), as well as the tac promoter (DeBoer et al., 1983<i>, Proc. Natl. Acad. Sci. USA </i>80: 21-25). Further promoters are described in “Useful proteins from recombinant bacteria” in Gilbert et al., 1980, <i>Scientific American </i>242: 74-94; and in Sambrook et al., 1989, supra. Examples of tandem promoters are disclosed in WO 99/43835.</p>
      <p id="p-00155-en" num="0153">Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for <i>Aspergillus nidulans </i>acetamidase, <i>Aspergillus niger </i>neutral alpha-amylase, <i>Aspergillus niger </i>acid stable alpha-amylase, <i>Aspergillus niger </i>or <i>Aspergillus awamori </i>glucoamylase (glaA), <i>Aspergillus oryzae </i>TAKA amylase, <i>Aspergillus oryzae </i>alkaline protease, <i>Aspergillus oryzae </i>triose phosphate isomerase, <i>Fusarium oxysporum </i>trypsin-like protease (WO 96/00787), <i>Fusarium venenatum </i>amyloglucosidase (WO 00/56900), <i>Fusarium venenatum </i>Dania (WO 00/56900), <i>Fusarium venenatum </i>Quinn (WO 00/56900), <i>Rhizomucor miehei </i>lipase, <i>Rhizomucor miehei </i>aspartic proteinase, <i>Trichoderma reesei </i>beta-glucosidase, <i>Trichoderma reesei </i>cellobiohydrolase I, <i>Trichoderma reesei </i>cellobiohydrolase II, <i>Trichoderma reesei </i>endoglucanase I, <i>Trichoderma reesei </i>endoglucanase II, <i>Trichoderma reesei </i>endoglucanase III, <i>Trichoderma reesei </i>endoglucanase IV, <i>Trichoderma reesei </i>endoglucanase V, <i>Trichoderma reesei </i>xylanase I, <i>Trichoderma reesei </i>xylanase II, <i>Trichoderma reesei </i>beta-xylosidase, as well as the NA2-tpi promoter (a modified promoter from an <i>Aspergillus </i>neutral alpha-amylase gene in which the untranslated leader has been replaced by an untranslated leader from an <i>Aspergillus </i>triose phosphate isomerase gene; non-limiting examples include modified promoters from an <i>Aspergillus niger </i>neutral alpha-amylase gene in which the untranslated leader has been replaced by an untranslated leader from an <i>Aspergillus nidulans </i>or <i>Aspergillus oryzae </i>triose phosphate isomerase gene); and mutant, truncated, and hybrid promoters thereof.</p>
      <p id="p-00156-en" num="0154">In a yeast host, useful promoters are obtained from the genes for <i>Saccharomyces cerevisiae enolase </i>(ENO-1), <i>Saccharomyces cerevisiae </i>galactokinase (GAL1), <i>Saccharomyces cerevisiae </i>alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2/GAP), <i>Saccharomyces cerevisiae </i>triose phosphate isomerase (TPI), <i>Saccharomyces cerevisiae </i>metallothionein (CUP1), and <i>Saccharomyces cerevisiae </i>3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos et al., 1992<i>, Yeast </i>8: 423-488.</p>
      <p id="p-00157-en" num="0155">The control sequence may also be a transcription terminator, which is recognized by a host cell to terminate transcription. The terminator is operably linked to the 3′-terminus of the polynucleotide encoding the polypeptide. Any terminator that is functional in the host cell may be used in the present invention.</p>
      <p id="p-00158-en" num="0156">Preferred terminators for bacterial host cells are obtained from the genes for <i>Bacillus clausii </i>alkaline protease (aprH), <i>Bacillus licheniformis </i>alpha-amylase (amyL), and <i>Escherichia coli </i>ribosomal RNA (rrnB).</p>
      <p id="p-00159-en" num="0157">Preferred terminators for filamentous fungal host cells are obtained from the genes for <i>Aspergillus nidulans </i>anthranilate synthase, <i>Aspergillus niger </i>glucoamylase, <i>Aspergillus niger </i>alpha-glucosidase, <i>Aspergillus oryzae </i>TAKA amylase, and <i>Fusarium oxysporum </i>trypsin-like protease.</p>
      <p id="p-00160-en" num="0158">Preferred terminators for yeast host cells are obtained from the genes for <i>Saccharomyces cerevisiae </i>enolase, <i>Saccharomyces cerevisiae </i>cytochrome C (CYC1), and <i>Saccharomyces cerevisiae </i>glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra.</p>
      <p id="p-00161-en" num="0159">The control sequence may also be an mRNA stabilizer region downstream of a promoter and upstream of the coding sequence of a gene which increases expression of the gene.</p>
      <p id="p-00162-en" num="0160">Examples of suitable mRNA stabilizer regions are obtained from a <i>Bacillus thuringiensis </i>cryIIIA gene (WO 94/25612) and a <i>Bacillus subtilis </i>SP82 gene (Hue et al., 1995<i>, Journal of Bacteriology </i>177: 3465-3471).</p>
      <p id="p-00163-en" num="0161">The control sequence may also be a leader, a nontranslated region of an mRNA that is important for translation by the host cell. The leader is operably linked to the 5′-terminus of the polynucleotide encoding the polypeptide. Any leader that is functional in the host cell may be used.</p>
      <p id="p-00164-en" num="0162">Preferred leaders for filamentous fungal host cells are obtained from the genes for <i>Aspergillus oryzae </i>TAKA amylase and <i>Aspergillus nidulans </i>triose phosphate isomerase.</p>
      <p id="p-00165-en" num="0163">Suitable leaders for yeast host cells are obtained from the genes for <i>Saccharomyces cerevisiae enolase </i>(ENO-1), <i>Saccharomyces cerevisiae </i>3-phosphoglycerate kinase, <i>Saccharomyces cerevisiae </i>alpha-factor, and <i>Saccharomyces cerevisiae </i>alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).</p>
      <p id="p-00166-en" num="0164">The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3′-terminus of the polynucleotide and, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence that is functional in the host cell may be used.</p>
      <p id="p-00167-en" num="0165">Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for <i>Aspergillus nidulans </i>anthranilate synthase, <i>Aspergillus niger </i>glucoamylase, <i>Aspergillus niger </i>alpha-glucosidase <i>Aspergillus oryzae </i>TAKA amylase, and <i>Fusarium oxysporum </i>trypsin-like protease.</p>
      <p id="p-00168-en" num="0166">Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995<i>, Mol. Cellular Biol</i>. 15: 5983-5990.</p>
      <p id="p-00169-en" num="0167">The control sequence may also be a signal peptide coding region that encodes a signal peptide linked to the N-terminus of a polypeptide and directs the polypeptide into the cell's secretory pathway. The 5′-end of the coding sequence of the polynucleotide may inherently contain a signal peptide coding sequence naturally linked in translation reading frame with the segment of the coding sequence that encodes the polypeptide. Alternatively, the 5′-end of the coding sequence may contain a signal peptide coding sequence that is foreign to the coding sequence. A foreign signal peptide coding sequence may be required where the coding sequence does not naturally contain a signal peptide coding sequence. Alternatively, a foreign signal peptide coding sequence may simply replace the natural signal peptide coding sequence in order to enhance secretion of the polypeptide. However, any signal peptide coding sequence that directs the expressed polypeptide into the secretory pathway of a host cell may be used.</p>
      <p id="p-00170-en" num="0168">Effective signal peptide coding sequences for bacterial host cells are the signal peptide coding sequences obtained from the genes for <i>Bacillus </i>NCIB 11837 maltogenic amylase, <i>Bacillus licheniformis </i>subtilisin, <i>Bacillus licheniformis </i>beta-lactamase, <i>Bacillus stearothermophilus </i>alpha-amylase, <i>Bacillus stearothermophilus </i>neutral proteases (nprT, nprS, nprM), and <i>Bacillus subtilis </i>prsA. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.</p>
      <p id="p-00171-en" num="0169">Effective signal peptide coding sequences for filamentous fungal host cells are the signal peptide coding sequences obtained from the genes for <i>Aspergillus niger </i>neutral amylase, <i>Aspergillus niger </i>glucoamylase, <i>Aspergillus oryzae </i>TAKA amylase, <i>Humicola insolens </i>cellulase, <i>Humicola insolens </i>endoglucanase V, <i>Humicola lanuginosa </i>lipase, and <i>Rhizomucor miehei </i>aspartic proteinase.</p>
      <p id="p-00172-en" num="0170">Useful signal peptides for yeast host cells are obtained from the genes for <i>Saccharomyces cerevisiae </i>alpha-factor and <i>Saccharomyces cerevisiae </i>invertase. Other useful signal peptide coding sequences are described by Romanos et al., 1992, supra.</p>
      <p id="p-00173-en" num="0171">The control sequence may also be a propeptide coding sequence that encodes a propeptide positioned at the N-terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to an active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding sequence may be obtained from the genes for <i>Bacillus subtilis </i>alkaline protease (aprE), <i>Bacillus subtilis </i>neutral protease (nprT), <i>Myceliophthora thermophila </i>laccase (WO 95/33836), <i>Rhizomucor miehei </i>aspartic proteinase, and <i>Saccharomyces cerevisiae </i>alpha-factor.</p>
      <p id="p-00174-en" num="0172">Where both signal peptide and propeptide sequences are present, the propeptide sequence is positioned next to the N-terminus of a polypeptide and the signal peptide sequence is positioned next to the N-terminus of the propeptide sequence.</p>
      <p id="p-00175-en" num="0173">It may also be desirable to add regulatory sequences that regulate expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those that cause expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the <i>Aspergillus niger </i>glucoamylase promoter, <i>Aspergillus oryzae </i>TAKA alpha-amylase promoter, and <i>Aspergillus oryzae </i>glucoamylase promoter may be used. Other examples of regulatory sequences are those that allow for gene amplification. In eukaryotic systems, these regulatory sequences include the dihydrofolate reductase gene that is amplified in the presence of methotrexate, and the metallothionein genes that are amplified with heavy metals. In these cases, the polynucleotide encoding the polypeptide would be operably linked with the regulatory sequence.</p>
      <heading id="h-00010-en" level="2">Expression Vectors</heading>
      <p id="p-00176-en" num="0174">The present invention also relates to recombinant expression vectors comprising a polynucleotide of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleotide and control sequences may be joined together to produce a recombinant expression vector that may include one or more convenient restriction sites to allow for insertion or substitution of the polynucleotide encoding the polypeptide at such sites. Alternatively, the polynucleotide may be expressed by inserting the polynucleotide or a nucleic acid construct comprising the polynucleotide into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.</p>
      <p id="p-00177-en" num="0175">The recombinant expression vector may be any vector (e.g., a plasmid or virus) that can be conveniently subjected to recombinant DNA procedures and can bring about expression of the polynucleotide. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector may be a linear or closed circular plasmid.</p>
      <p id="p-00178-en" num="0176">The vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one that, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell, or a transposon, may be used.</p>
      <p id="p-00179-en" num="0177">The vector preferably contains one or more selectable markers that permit easy selection of transformed, transfected, transduced, or the like cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.</p>
      <p id="p-00180-en" num="0178">Examples of bacterial selectable markers are <i>Bacillus licheniformis </i>or <i>Bacillus subtilis </i>dal genes, or markers that confer antibiotic resistance such as ampicillin, chloramphenicol, kanamycin, neomycin, spectinomycin, or tetracycline resistance. Suitable markers for yeast host cells include, but are not limited to, ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a filamentous fungal host cell include, but are not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5′-phosphate decarboxylase), sC (sulfate adenyltransferase), and trpC (anthranilate synthase), as well as equivalents thereof. Preferred for use in an <i>Aspergillus </i>cell are <i>Aspergillus nidulans </i>or <i>Aspergillus oryzae </i>amdS and pyrG genes and a <i>Streptomyces hygroscopicus </i>bar gene.</p>
      <p id="p-00181-en" num="0179">The vector preferably contains an element(s) that permits integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.</p>
      <p id="p-00182-en" num="0180">For integration into the host cell genome, the vector may rely on the polynucleotide's sequence encoding the polypeptide or any other element of the vector for integration into the genome by homologous or non-homologous recombination. Alternatively, the vector may contain additional polynucleotides for directing integration by homologous recombination into the genome of the host cell at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, 400 to 10,000 base pairs, and 800 to 10,000 base pairs, which have a high degree of sequence identity to the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding polynucleotides. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.</p>
      <p id="p-00183-en" num="0181">For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. The origin of replication may be any plasmid replicator mediating autonomous replication that functions in a cell. The term “origin of replication” or “plasmid replicator” means a polynucleotide that enables a plasmid or vector to replicate in vivo.</p>
      <p id="p-00184-en" num="0182">Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in <i>E. coli</i>, and pUB110, pE194, pTA1060, and pAMβ1 permitting replication in <i>Bacillus. </i></p>
      <p id="p-00185-en" num="0183">Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6.</p>
      <p id="p-00186-en" num="0184">Examples of origins of replication useful in a filamentous fungal cell are AMA1 and ANSI (Gems et al., 1991, Gene 98: 61-67; Cullen et al., 1987, Nucleic Acids Res. 15: 9163-9175; WO 00/24883). Isolation of the AMA1 gene and construction of plasmids or vectors comprising the gene can be accomplished according to the methods disclosed in WO 00/24883.</p>
      <p id="p-00187-en" num="0185">More than one copy of a polynucleotide of the present invention may be inserted into a host cell to increase production of a polypeptide. An increase in the copy number of the polynucleotide can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the polynucleotide where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the polynucleotide, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.</p>
      <p id="p-00188-en" num="0186">The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra).</p>
      <heading id="h-00011-en" level="2">Host Cells</heading>
      <p id="p-00189-en" num="0187">The present invention also relates to recombinant host cells, comprising a polynucleotide of the present invention operably linked to one or more control sequences that direct the production of a polypeptide of the present invention. A construct or vector comprising a polynucleotide is introduced into a host cell so that the construct or vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term “host cell” encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.</p>
      <p id="p-00190-en" num="0188">The host cell may be any cell useful in the recombinant production of a polypeptide of the present invention, e.g., a prokaryote or a eukaryote.</p>
      <p id="p-00191-en" num="0189">The prokaryotic host cell may be any Gram-positive or Gram-negative bacterium. Gram-positive bacteria include, but are not limited to, <i>Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus</i>, and <i>Streptomyces</i>. Gram-negative bacteria include, but are not limited to, <i>Campylobacter, E. coli, Flavobacterium, Fusobacterium, Helicobacter, Ilyobacter, Neisseria, Pseudomonas, Salmonella</i>, and <i>Ureaplasma. </i></p>
      <p id="p-00192-en" num="0190">The bacterial host cell may be any <i>Bacillus </i>cell including, but not limited to, <i>Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis</i>, and <i>Bacillus thuringiensis </i>cells.</p>
      <p id="p-00193-en" num="0191">The bacterial host cell may also be any <i>Streptococcus </i>cell including, but not limited to, <i>Streptococcus equisimilis, Streptococcus pyogenes, Streptococcus uberis</i>, and <i>Streptococcus equi </i>subsp. <i>Zooepidemicus </i>cells.</p>
      <p id="p-00194-en" num="0192">The bacterial host cell may also be any <i>Streptomyces </i>cell including, but not limited to, <i>Streptomyces achromogenes, Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces griseus</i>, and <i>Streptomyces lividans </i>cells.</p>
      <p id="p-00195-en" num="0193">The introduction of DNA into a <i>Bacillus </i>cell may be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979<i>, Mol. Gen. Genet. </i>168: 111-115), competent cell transformation (see, e.g., Young and Spizizen, 1961, <i>J. Bacteriol. </i>81: 823-829, or Dubnau and Davidoff-Abelson, 1971<i>, J. Mol. Biol. </i>56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, <i>Biotechniques </i>6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, <i>J. Bacteriol. </i>169: 5271-5278). The introduction of DNA into an <i>E. coli </i>cell may be effected by protoplast transformation (see, e.g., Hanahan, 1983<i>, J. Mol. Biol. </i>166: 557-580) or electroporation (see, e.g., Dower et al., 1988<i>, Nucleic Acids Res. </i>16: 6127-6145). The introduction of DNA into a <i>Streptomyces </i>cell may be effected by protoplast transformation, electroporation (see, e.g., Gong et al., 2004, <i>Folia Microbiol</i>. (Praha) 49: 399-405), conjugation (see, e.g., Mazodier et al., 1989, <i>J. Bacteriol. </i>171: 3583-3585), or transduction (see, e.g., Burke et al., 2001<i>, Proc. Natl. Acad. Sci. USA </i>98: 6289-6294). The introduction of DNA into a <i>Pseudomonas </i>cell may be effected by electroporation (see, e.g., Choi et al., 2006<i>, J. Microbiol. Methods </i>64: 391-397) or conjugation (see, e.g., Pinedo and Smets, 2005, <i>Appl. Environ. Microbiol. </i>71: 51-57). The introduction of DNA into a <i>Streptococcus </i>cell may be effected by natural competence (see, e.g., Perry and Kuramitsu, 1981, <i>Infect. Immun. </i>32: 1295-1297), protoplast transformation (see, e.g., Catt and Jollick, 1991, <i>Microbios </i>68: 189-207), electroporation (see, e.g., Buckley et al., 1999, <i>Appl. Environ. Microbiol. </i>65: 3800-3804), or conjugation (see, e.g., Clewell, 1981<i>, Microbiol. Rev. </i>45: 409-436). However, any method known in the art for introducing DNA into a host cell can be used.</p>
      <p id="p-00196-en" num="0194">The host cell may also be a eukaryote, such as a mammalian, insect, plant, or fungal cell.</p>
      <p id="p-00197-en" num="0195">The host cell may be a fungal cell. “Fungi” as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota as well as the Oomycota and all mitosporic fungi (as defined by Hawksworth et al., <i>In, Ainsworth and Bisby's Dictionary of The Fungi</i>, 8th edition, 1995, CAB International, University Press, Cambridge, UK).</p>
      <p id="p-00198-en" num="0196">The fungal host cell may be a yeast cell. “Yeast” as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (Skinner, Passmore, and Davenport, editors, <i>Soc. App. Bacteriol. Symposium Series </i>No. 9, 1980).</p>
      <p id="p-00199-en" num="0197">The yeast host cell may be a <i>Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces</i>, or <i>Yarrowia </i>cell, such as a <i>Kluyveromyces lactis, Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis, Saccharomyces oviformis</i>, or <i>Yarrowia lipolytica </i>cell.</p>
      <p id="p-00200-en" num="0198">The fungal host cell may be a filamentous fungal cell. “Filamentous fungi” include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as <i>Saccharomyces cerevisiae </i>is by budding of a unicellular thallus and carbon catabolism may be fermentative.</p>
      <p id="p-00201-en" num="0199">The filamentous fungal host cell may be an <i>Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes</i>, or <i>Trichoderma </i>cell.</p>
      <p id="p-00202-en" num="0200">For example, the filamentous fungal host cell may be an <i>Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Bjerkandera adusta, Ceriporiopsis aneirina, Ceriporiopsis caregiea, Ceriporiopsis gilvescens, Ceriporiopsis pannocinta, Ceriporiopsis rivulosa, Ceriporiopsis subrufa, Ceriporiopsis subvermispora, Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Coprinus cinereus, Coriolus hirsutus, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola insolens, Humicola lanuginosa, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium purpurogenum, Phanerochaete chrysosporium, Phlebia radiata, Pleurotus eryngii, Thielavia terrestris, Trametes villosa, Trametes versicolor, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei</i>, or <i>Trichoderma viride </i>cell.</p>
      <p id="p-00203-en" num="0201">Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transformation of <i>Aspergillus </i>and <i>Trichoderma </i>host cells are described in EP 238023, Yelton et al., 1984<i>, Proc. Natl. Acad. Sci. USA </i>81: 1470-1474, and Christensen et al., 1988, <i>Bio/Technology </i>6: 1419-1422. Suitable methods for transforming <i>Fusarium </i>species are described by Malardier et al., 1989, <i>Gene </i>78: 147-156, and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J. N. and Simon, M. I., editors, Guide to Yeast Genetics and Molecular Biology, <i>Methods in Enzymology</i>, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, <i>J. Bacteriol. </i>153: 163; and Hinnen et al., 1978<i>, Proc. Natl. Acad. Sci. USA </i>75: 1920.</p>
      <heading id="h-00012-en" level="2">Methods of Production</heading>
      <p id="p-00204-en" num="0202">The present invention also relates to methods of producing a polypeptide of the present invention, comprising (a) cultivating a cell, which in its wild-type form produces the polypeptide, under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide. In a preferred aspect, the cell is a <i>Lentinus </i>cell. In a more preferred aspect, the cell is a <i>Lentinus similis </i>cell. The present invention also relates to methods of producing a polypeptide of the present invention, comprising (a) cultivating a recombinant host cell of the present invention under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.</p>
      <p id="p-00205-en" num="0203">The host cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, or small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.</p>
      <p id="p-00206-en" num="0204">The polypeptide may be detected using methods known in the art that are specific for the polypeptides. These detection methods include, but are not limited to, use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide.</p>
      <p id="p-00207-en" num="0205">The polypeptide may be recovered using methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.</p>
      <p id="p-00208-en" num="0206">The polypeptide may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., <i>Protein Purification</i>, Janson and Ryden, editors, VCH Publishers, New York, 1989) to obtain substantially pure polypeptides.</p>
      <p id="p-00209-en" num="0207">In an alternative aspect, the polypeptide is not recovered, but rather a host cell of the present invention expressing the polypeptide is used as a source of the polypeptide.</p>
      <heading id="h-00013-en" level="2">Plants</heading>
      <p id="p-00210-en" num="0208">The present invention also relates to isolated plants, e.g., a transgenic plant, plant part, or plant cell, comprising a polynucleotide of the present invention so as to express and produce a polypeptide or domain in recoverable quantities. The polypeptide or domain may be recovered from the plant or plant part. Alternatively, the plant or plant part containing the polypeptide or domain may be used as such for improving the quality of a food or feed, e.g., improving nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor.</p>
      <p id="p-00211-en" num="0209">The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot). Examples of monocot plants are grasses, such as meadow grass (blue grass, <i>Poa</i>), forage grass such as <i>Festuca, Lolium</i>, temperate grass, such as <i>Agrostis</i>, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum, and maize (corn).</p>
      <p id="p-00212-en" num="0210">Examples of dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, rape seed, and the closely related model organism <i>Arabidopsis thaliana. </i></p>
      <p id="p-00213-en" num="0211">Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers as well as the individual tissues comprising these parts, e.g., epidermis, mesophyll, parenchyme, vascular tissues, meristems. Specific plant cell compartments, such as chloroplasts, apoplasts, mitochondria, vacuoles, peroxisomes and cytoplasm are also considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part. Likewise, plant parts such as specific tissues and cells isolated to facilitate the utilization of the invention are also considered plant parts, e.g., embryos, endosperms, aleurone and seed coats.</p>
      <p id="p-00214-en" num="0212">Also included within the scope of the present invention are the progeny of such plants, plant parts, and plant cells.</p>
      <p id="p-00215-en" num="0213">The transgenic plant or plant cell expressing the polypeptide or domain may be constructed in accordance with methods known in the art. In short, the plant or plant cell is constructed by incorporating one or more expression constructs encoding the polypeptide or domain into the plant host genome or chloroplast genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.</p>
      <p id="p-00216-en" num="0214">The expression construct is conveniently a nucleic acid construct that comprises a polynucleotide encoding a polypeptide or domain operably linked with appropriate regulatory sequences required for expression of the polynucleotide in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying plant cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).</p>
      <p id="p-00217-en" num="0215">The choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences, is determined, for example, on the basis of when, where, and how the polypeptide or domain is desired to be expressed. For instance, the expression of the gene encoding a polypeptide or domain may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are, for example, described by Tague et al., 1988, <i>Plant Physiology </i>86: 506.</p>
      <p id="p-00218-en" num="0216">For constitutive expression, the 35S-CaMV, the maize ubiquitin 1, or the rice actin 1 promoter may be used (Franck et al., 1980<i>, Cell </i>21: 285-294; Christensen et al., 1992, <i>Plant Mol. Biol</i>. 18: 675-689; Zhang et al., 1991, <i>Plant Cell </i>3: 1155-1165). Organ-specific promoters may be, for example, a promoter from storage sink tissues such as seeds, potato tubers, and fruits (Edwards and Coruzzi, 1990<i>, Ann. Rev. Genet. </i>24: 275-303), or from metabolic sink tissues such as meristems (Ito et al., 1994, <i>Plant Mol. Biol. </i>24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin, or albumin promoter from rice (Wu et al., 1998, <i>Plant Cell Physiol. </i>39: 885-889), a <i>Vicia faba </i>promoter from the legumin B4 and the unknown seed protein gene from <i>Vicia faba </i>(Conrad et al., 1998, <i>J. Plant Physiol. </i>152: 708-711), a promoter from a seed oil body protein (Chen et al., 1998, <i>Plant Cell Physiol. </i>39: 935-941), the storage protein napA promoter from <i>Brassica napus</i>, or any other seed specific promoter known in the art, e.g., as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the rbcs promoter from rice or tomato (Kyozuka et al., 1993, <i>Plant Physiol. </i>102: 991-1000), the chlorella virus adenine methyltransferase gene promoter (Mitra and Higgins, 1994, <i>Plant Mol. Biol. </i>26: 85-93), the aldP gene promoter from rice (Kagaya et al., 1995<i>, Mol. Gen. Genet. </i>248: 668-674), or a wound inducible promoter such as the potato pin2 promoter (Xu et al., 1993, <i>Plant Mol. Biol. </i>22: 573-588). Likewise, the promoter may be induced by abiotic treatments such as temperature, drought, or alterations in salinity or induced by exogenously applied substances that activate the promoter, e.g., ethanol, oestrogens, plant hormones such as ethylene, abscisic acid, and gibberellic acid, and heavy metals.</p>
      <p id="p-00219-en" num="0217">A promoter enhancer element may also be used to achieve higher expression of a polypeptide or domain in the plant. For instance, the promoter enhancer element may be an intron that is placed between the promoter and the polynucleotide encoding a polypeptide or domain. For instance, Xu et al., 1993, supra, disclose the use of the first intron of the rice actin 1 gene to enhance expression.</p>
      <p id="p-00220-en" num="0218">The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.</p>
      <p id="p-00221-en" num="0219">The nucleic acid construct is incorporated into the plant genome according to conventional techniques known in the art, including <i>Agrobacterium</i>-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biolistic transformation, and electroporation (Gasser et al., 1990, <i>Science </i>244: 1293; Potrykus, 1990, <i>Bio/Technology </i>8: 535; Shimamoto et al., 1989, <i>Nature </i>338: 274).</p>
      <p id="p-00222-en" num="0220">
        <i>Agrobacterium tumefaciens</i>-mediated gene transfer is a method for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992, <i>Plant Mol. Biol. </i>19: 15-38) and for transforming monocots, although other transformation methods may be used for these plants. A method for generating transgenic monocots is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, <i>Plant J. </i>2: 275-281; Shimamoto, 1994, <i>Curr. Opin. Biotechnol. </i>5: 158-162; Vasil et al., 1992, <i>Bio/Technology </i>10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh et al., 1993, <i>Plant Mol. Biol. </i>21: 415-428. Additional transformation methods include those described in U.S. Pat. Nos. 6,395,966 and 7,151,204 (both of which are herein incorporated by reference in their entirety).</p>
      <p id="p-00223-en" num="0221">Following transformation, the transformants having incorporated the expression construct are selected and regenerated into whole plants according to methods well known in the art. Often the transformation procedure is designed for the selective elimination of selection genes either during regeneration or in the following generations by using, for example, co-transformation with two separate T-DNA constructs or site specific excision of the selection gene by a specific recombinase.</p>
      <p id="p-00224-en" num="0222">In addition to direct transformation of a particular plant genotype with a construct of the present invention, transgenic plants may be made by crossing a plant having the construct to a second plant lacking the construct. For example, a construct encoding a polypeptide or domain can be introduced into a particular plant variety by crossing, without the need for ever directly transforming a plant of that given variety. Therefore, the present invention encompasses not only a plant directly regenerated from cells which have been transformed in accordance with the present invention, but also the progeny of such plants. As used herein, progeny may refer to the offspring of any generation of a parent plant prepared in accordance with the present invention. Such progeny may include a DNA construct prepared in accordance with the present invention. Crossing results in the introduction of a transgene into a plant line by cross pollinating a starting line with a donor plant line. Non-limiting examples of such steps are described in U.S. Pat. No. 7,151,204.</p>
      <p id="p-00225-en" num="0223">Plants may be generated through a process of backcross conversion. For example, plants include plants referred to as a backcross converted genotype, line, inbred, or hybrid.</p>
      <p id="p-00226-en" num="0224">Genetic markers may be used to assist in the introgression of one or more transgenes of the invention from one genetic background into another. Marker assisted selection offers advantages relative to conventional breeding in that it can be used to avoid errors caused by phenotypic variations. Further, genetic markers may provide data regarding the relative degree of elite germplasm in the individual progeny of a particular cross. For example, when a plant with a desired trait which otherwise has a non-agronomically desirable genetic background is crossed to an elite parent, genetic markers may be used to select progeny which not only possess the trait of interest, but also have a relatively large proportion of the desired germplasm. In this way, the number of generations required to introgress one or more traits into a particular genetic background is minimized.</p>
      <p id="p-00227-en" num="0225">The present invention also relates to methods of producing a polypeptide or domain of the present invention comprising (a) cultivating a transgenic plant or a plant cell comprising a polynucleotide encoding the polypeptide or domain under conditions conducive for production of the polypeptide or domain; and (b) recovering the polypeptide or domain.</p>
      <heading id="h-00014-en" level="2">Compositions</heading>
      <p id="p-00228-en" num="0226">The present invention also relates to compositions comprising a polypeptide of the present invention. Preferably, the compositions are enriched in such a polypeptide. The term “enriched” indicates that the cellulolytic enhancing activity of the composition has been increased, e.g., with an enrichment factor of at least 1.1.</p>
      <p id="p-00229-en" num="0227">The composition may comprise a polypeptide of the present invention as the major enzymatic component, e.g., a mono-component composition. Alternatively, the composition may comprise multiple enzymatic activities, such as one or more (several) enzymes selected from the group consisting of a cellulase, a hemicellulase, an expansin, an esterase, a laccase, a ligninolytic enzyme, a pectinase, a peroxidase, a protease, and a swollenin.</p>
      <p id="p-00230-en" num="0228">The polypeptide compositions may be prepared in accordance with methods known in the art and may be in the form of a liquid or a dry composition. For instance, the polypeptide composition may be in the form of a granulate or a microgranulate. The polypeptide to be included in the composition may be stabilized in accordance with methods known in the art.</p>
      <p id="p-00231-en" num="0229">Examples are given below of preferred uses of the polypeptide compositions of the invention. The dosage of the polypeptide composition of the invention and other conditions under which the composition is used may be determined on the basis of methods known in the art.</p>
      <heading id="h-00015-en" level="2">Uses</heading>
      <p id="p-00232-en" num="0230">The present invention is also directed to the following processes for using the polypeptides having cellulolytic enhancing activity, or compositions thereof.</p>
      <p id="p-00233-en" num="0231">The present invention also relates to processes for degrading a cellulosic material, comprising: treating the cellulosic material with an enzyme composition in the presence of a polypeptide having cellulolytic enhancing activity of the present invention. In one aspect, the processes further comprise recovering the degraded or converted cellulosic material. Soluble products of degradation or conversion of the cellulosic material can be separated from insoluble cellulosic material using a method known in the art such as, for example, centrifugation, filtration, or gravity settling.</p>
      <p id="p-00234-en" num="0232">In another aspect, an effective amount of a polypeptide having cellulolytic enhancing activity to the cellulosic material is about 0.01 to about 50.0 mg, e.g., about 0.01 to about 40 mg, about 0.01 to about 30 mg, about 0.01 to about 20 mg, about 0.01 to about 10 mg, about 0.01 to about 5 mg, about 0.025 to about 1.5 mg, about 0.05 to about 1.25 mg, about 0.075 to about 1.25 mg, about 0.1 to about 1.25 mg, about 0.15 to about 1.25 mg, or about 0.25 to about 1.0 mg per g of the cellulosic material.</p>
      <p id="p-00235-en" num="0233">In another aspect, an effective amount of a polypeptide having cellulolytic enhancing activity to cellulolytic or hemicellulolytic enzyme is about 0.005 to about 1.0 g, e.g., about 0.01 to about 1.0 g, about 0.15 to about 0.75 g, about 0.15 to about 0.5 g, about 0.1 to about 0.5 g, about 0.1 to about 0.25 g, or about 0.05 to about 0.2 g per g of cellulolytic or hemicellulolytic enzyme.</p>
      <p id="p-00236-en" num="0234">The polypeptides having cellulolytic enzyme activity or hemicellulolytic enzyme activity as well as other proteins/polypeptides useful in the degradation of the cellulosic material (collectively hereinafter “polypeptides having enzyme activity”) can be derived or obtained from any suitable origin, including, bacterial, fungal, yeast, plant, or mammalian origin. The term “obtained” also means herein that the enzyme may have been produced recombinantly in a host organism employing methods described herein, wherein the recombinantly produced enzyme is either native or foreign to the host organism or has a modified amino acid sequence, e.g., having one or more (e.g., several) amino acids that are deleted, inserted and/or substituted, i.e., a recombinantly produced enzyme that is a mutant and/or a fragment of a native amino acid sequence or an enzyme produced by nucleic acid shuffling processes known in the art. Encompassed within the meaning of a native enzyme are natural variants and within the meaning of a foreign enzyme are variants obtained recombinantly, such as by site-directed mutagenesis or shuffling.</p>
      <p id="p-00237-en" num="0235">A polypeptide having enzyme activity may be a bacterial polypeptide. For example, the polypeptide may be a Gram positive bacterial polypeptide such as a <i>Bacillus, Streptococcus, Streptomyces, Staphylococcus, Enterococcus, Lactobacillus, Lactococcus, Clostridium, Geobacillus, Caldicellulosiruptor, Acidothermus, Thermobifidia</i>, or <i>Oceanobacillus </i>polypeptide having enzyme activity, or a Gram negative bacterial polypeptide such as an <i>E. coli, Pseudomonas, Salmonella, Campylobacter, Helicobacter, Flavobacterium, Fusobacterium, Ilyobacter, Neisseria</i>, or <i>Ureaplasma </i>polypeptide having enzyme activity.</p>
      <p id="p-00238-en" num="0236">In one aspect, the polypeptide is a <i>Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis</i>, or <i>Bacillus thuringiensis </i>polypeptide having enzyme activity.</p>
      <p id="p-00239-en" num="0237">In another aspect, the polypeptide is a <i>Streptococcus equisimilis, Streptococcus pyogenes, Streptococcus uberis</i>, or <i>Streptococcus equi </i>subsp. <i>Zooepidemicus </i>polypeptide having enzyme activity.</p>
      <p id="p-00240-en" num="0238">In another aspect, the polypeptide is a <i>Streptomyces achromogenes, Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces griseus</i>, or <i>Streptomyces lividans </i>polypeptide having enzyme activity.</p>
      <p id="p-00241-en" num="0239">The polypeptide having enzyme activity may also be a fungal polypeptide, and more preferably a yeast polypeptide such as a <i>Candida, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces</i>, or <i>Yarrowia </i>polypeptide having enzyme activity; or more preferably a filamentous fungal polypeptide such as an <i>Acremonium, Agaricus, Alternaria, Aspergillus, Aureobasidium, Botryosphaeria, Ceriporiopsis, Chaetomidium, Chrysosporium, Claviceps, Cochliobolus, Coprinopsis, Coptotermes, Corynascus, Cryphonectria, Cryptococcus, Diplodia, Exidia, Filibasidium, Fusarium, Gibberella, Holomastigotoides, Humicola, Irpex, Lentinula, Leptospaeria, Magnaporthe, Melanocarpus, Meripilus, Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Piromyces, Poitrasia, Pseudoplectania, Pseudotrichonympha, Rhizomucor, Schizophyllum, Scytalidium, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma, Trichophaea, Verticillium, Volvariella</i>, or <i>Xylaria </i>polypeptide having enzyme activity.</p>
      <p id="p-00242-en" num="0240">In one aspect, the polypeptide is a <i>Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis</i>, or <i>Saccharomyces oviformis </i>polypeptide having enzyme activity.</p>
      <p id="p-00243-en" num="0241">In another aspect, the polypeptide is an <i>Acremonium cellulolyticus, Aspergillus aculeatus, Aspergillus awamori, Aspergillus fumigatus, Aspergillus foetidus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium tropicum, Chrysosporium merdarium, Chrysosporium inops, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium zonatum, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola grisea, Humicola insolens, Humicola lanuginosa, Irpex lacteus, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium funiculosum, Penicillium purpurogenum, Phanerochaete chrysosporium, Thielavia achromatica, Thielavia albomyces, Thielavia albopilosa, Thielavia australeinsis, Thielavia fimeti, Thielavia microspora, Thielavia ovispora, Thielavia peruviana, Thielavia spededonium, Thielavia setosa, Thielavia subthermophila, Thielavia terrestris, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei, Trichoderma viride</i>, or <i>Trichophaea saccata </i>polypeptide having enzyme activity.</p>
      <p id="p-00244-en" num="0242">Chemically modified or protein engineered mutants of polypeptides having enzyme activity may also be used.</p>
      <p id="p-00245-en" num="0243">One or more (e.g., several) components of the enzyme composition may be a recombinant component, i.e., produced by cloning of a DNA sequence encoding the single component and subsequent cell transformed with the DNA sequence and expressed in a host (see, for example, WO 91/17243 and WO 91/17244). The host is preferably a heterologous host (enzyme is foreign to host), but the host may under certain conditions also be a homologous host (enzyme is native to host). Monocomponent cellulolytic proteins may also be prepared by purifying such a protein from a fermentation broth.</p>
      <p id="p-00246-en" num="0244">In one aspect, the one or more (e.g., several) cellulolytic enzymes comprise a commercial cellulolytic enzyme preparation. Examples of commercial cellulolytic enzyme preparations suitable for use in the present invention include, for example, CELLIC® CTec (Novozymes NS), CELLIC® CTec2 (Novozymes NS), CELLIC® CTec3 (Novozymes NS), CELLUCLAST™ (Novozymes NS), NOVOZYM™ 188 (Novozymes NS), CELLUZYME™ (Novozymes NS), CEREFLO™ (Novozymes NS), and ULTRAFLO™ (Novozymes NS), ACCELERASE™ (Genencor Int.), LAMINEX™ (Genencor Int.), SPEZYME™ CP (Genencor Int.), FILTRASE® NL (DSM); METHAPLUS® S/L 100 (DSM), ROHAMENT™ 7069 W (Rohm GmbH), FIBREZYME® LDI (Dyadic International, Inc.), FIBREZYME® LBR (Dyadic International, Inc.), or VISCOSTAR® 150L (Dyadic International, Inc.). The cellulase enzymes are added in amounts effective from about 0.001 to about 5.0 wt % of solids, e.g., about 0.025 to about 4.0 wt % of solids or about 0.005 to about 2.0 wt % of solids.</p>
      <p id="p-00247-en" num="0245">In one aspect, the GH61 polypeptide having cellulolytic enhancing activity is used in the presence of a soluble activating divalent metal cation according to WO 2008/151043, e.g., manganese sulfate.</p>
      <p id="p-00248-en" num="0246">In another aspect, the GH61 polypeptide having cellulolytic enhancing activity is used in the presence of a dioxy compound, a bicylic compound, a heterocyclic compound, a nitrogen-containing compound, a quinone compound, a sulfur-containing compound, or a liquor obtained from a pretreated cellulosic material such as pretreated corn stover (PCS).</p>
      <p id="p-00249-en" num="0247">The dioxy compound may include any suitable compound containing two or more oxygen atoms. In some aspects, the dioxy compounds contain a substituted aryl moiety as described herein. The dioxy compounds may comprise one or more (e.g., several) hydroxyl and/or hydroxyl derivatives, but also include substituted aryl moieties lacking hydroxyl and hydroxyl derivatives. Non-limiting examples of the dioxy compounds include pyrocatechol or catechol; caffeic acid; 3,4-dihydroxybenzoic acid; 4-tert-butyl-5-methoxy-1,2-benzenediol; pyrogallol; gallic acid; methyl-3,4,5-trihydroxybenzoate; 2,3,4-trihydroxybenzophenone; 2,6-dimethoxyphenol; sinapinic acid; 3,5-dihydroxybenzoic acid; 4-chloro-1,2-benzenediol; 4-nitro-1,2-benzenediol; tannic acid; ethyl gallate; methyl glycolate; dihydroxyfumaric acid; 2-butyne-1,4-diol; (croconic acid; 1,3-propanediol; tartaric acid; 2,4-pentanediol; 3-ethyoxy-1,2-propanediol; 2,4,4′-trihydroxybenzophenone; cis-2-butene-1,4-diol; 3,4-dihydroxy-3-cyclobutene-1,2-dione; dihydroxyacetone; acrolein acetal; methyl-4-hydroxybenzoate; 4-hydroxybenzoic acid; and methyl-3,5-dimethoxy-4-hydroxybenzoate; or a salt or solvate thereof.</p>
      <p id="p-00250-en" num="0248">The bicyclic compound may include any suitable substituted fused ring system as described herein. The compounds may comprise one or more (e.g., several) additional rings, and are not limited to a specific number of rings unless otherwise stated. In one aspect, the bicyclic compound is a flavonoid. In another aspect, the bicyclic compound is an optionally substituted isoflavonoid. In another aspect, the bicyclic compound is an optionally substituted flavylium ion, such as an optionally substituted anthocyanidin or optionally substituted anthocyanin, or derivative thereof. Non-limiting examples of the bicyclic compounds include epicatechin; quercetin; myricetin; taxifolin; kaempferol; morin; acacetin; naringenin; isorhamnetin; apigenin; cyanidin; cyanin; kuromanin; keracyanin; or a salt or solvate thereof.</p>
      <p id="p-00251-en" num="0249">The heterocyclic compound may be any suitable compound, such as an optionally substituted aromatic or non-aromatic ring comprising a heteroatom, as described herein. In one aspect, the heterocyclic is a compound comprising an optionally substituted heterocycloalkyl moiety or an optionally substituted heteroaryl moiety. In another aspect, the optionally substituted heterocycloalkyl moiety or optionally substituted heteroaryl moiety is an optionally substituted 5-membered heterocycloalkyl or an optionally substituted 5-membered heteroaryl moiety. In another aspect, the optionally substituted heterocycloalkyl or optionally substituted heteroaryl moiety is an optionally substituted moiety selected from pyrazolyl, furanyl, imidazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidyl, pyridazinyl, thiazolyl, triazolyl, thienyl, dihydrothieno-pyrazolyl, thianaphthenyl, carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, benzooxazolyl, benzimidazolyl, isoquinolinyl, isoindolyl, acridinyl, benzoisazolyl, dimethylhydantoin, pyrazinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, indolyl, diazepinyl, azepinyl, thiepinyl, piperidinyl, and oxepinyl. In another aspect, the optionally substituted heterocycloalkyl moiety or optionally substituted heteroaryl moiety is an optionally substituted furanyl. Non-limiting examples of the heterocyclic compounds include (1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one; 4-hydroxy-5-methyl-3-furanone; 5-hydroxy-2(5H)-furanone; [1,2-dihydroxyethyl]furan-2,3,4(5H)-trione; α-hydroxy-γ-butyrolactone; ribonic γ-lactone; aldohexuronicaldohexuronic acid γ-lactone; gluconic acid δ-lactone; 4-hydroxycoumarin; dihydrobenzofuran; 5-(hydroxymethyl)furfural; furoin; 2(5H)-furanone; 5,6-dihydro-2H-pyran-2-one; and 5,6-dihydro-4-hydroxy-6-methyl-2H-pyran-2-one; or a salt or solvate thereof.</p>
      <p id="p-00252-en" num="0250">The nitrogen-containing compound may be any suitable compound with one or more nitrogen atoms. In one aspect, the nitrogen-containing compound comprises an amine, imine, hydroxylamine, or nitroxide moiety. Non-limiting examples of the nitrogen-containing compounds include acetone oxime; violuric acid; pyridine-2-aldoxime; 2-aminophenol; 1,2-benzenediamine; 2,2,6,6-tetramethyl-1-piperidinyloxy; 5,6,7,8-tetrahydrobiopterin; 6,7-d imethyl-5,6,7,8-tetrahydropterine; and maleamic acid; or a salt or solvate thereof.</p>
      <p id="p-00253-en" num="0251">The quinone compound may be any suitable compound comprising a quinone moiety as described herein. Non-limiting examples of the quinone compounds include 1,4-benzoquinone; 1,4-naphthoquinone; 2-hydroxy-1,4-naphthoquinone; 2,3-dimethoxy-5-methyl-1,4-benzoquinone or coenzyme Q<sub>0</sub>; 2,3,5,6-tetramethyl-1,4-benzoquinone or duroquinone; 1,4-dihydroxyanthraquinone; 3-hydroxy-1-methyl-5,6-indolinedione or adrenochrome; 4-tert-butyl-5-methoxy-1,2-benzoquinone; pyrroloquinoline quinone; or a salt or solvate thereof.</p>
      <p id="p-00254-en" num="0252">The sulfur-containing compound may be any suitable compound comprising one or more sulfur atoms. In one aspect, the sulfur-containing comprises a moiety selected from thionyl, thioether, sulfinyl, sulfonyl, sulfamide, sulfonamide, sulfonic acid, and sulfonic ester. Non-limiting examples of the sulfur-containing compounds include ethanethiol; 2-propanethiol; 2-propene-1-thiol; 2-mercaptoethanesulfonic acid; benzenethiol; benzene-1,2-dithiol; cysteine; methionine; glutathione; cystine; or a salt or solvate thereof.</p>
      <p id="p-00255-en" num="0253">In one aspect, an effective amount of such a compound described above to cellulosic material as a molar ratio to glucosyl units of cellulose is about 10<sup>−6 </sup>to about 10, e.g., about 10<sup>−6 </sup>to about 7.5, about 10<sup>−6 </sup>to about 5, about 10<sup>−6 </sup>to about 2.5, about 10<sup>−6 </sup>to about 1, about 10<sup>−6 </sup>to about 1, about 10<sup>−5 </sup>to about 10<sup>−1</sup>, about 10<sup>−4 </sup>to about 10<sup>−1</sup>, about 10<sup>−3 </sup>to about 10<sup>−1</sup>, or about 10<sup>−3 </sup>to about 10<sup>−2</sup>. In another aspect, an effective amount of such a compound described above is about 0.1 μM to about 1 M, e.g., about 0.5 μM to about 0.75 M, about 0.75 μM to about 0.5 M, about 1 μM to about 0.25 M, about 1 μM to about 0.1 M, about 5 μM to about 50 mM, about 10 μM to about 25 mM, about 50 μM to about 25 mM, about 10 μM to about 10 mM, about 5 μM to about 5 mM, or about 0.1 mM to about 1 mM.</p>
      <p id="p-00256-en" num="0254">The term “liquor” means the solution phase, either aqueous, organic, or a combination thereof, arising from treatment of a lignocellulose and/or hemicellulose material in a slurry, or monosaccharides thereof, e.g., xylose, arabinose, mannose, etc., under conditions as described herein, and the soluble contents thereof. A liquor for cellulolytic enhancement of a GH61 polypeptide can be produced by treating a lignocellulose or hemicellulose material (or feedstock) by applying heat and/or pressure, optionally in the presence of a catalyst, e.g., acid, optionally in the presence of an organic solvent, and optionally in combination with physical disruption of the material, and then separating the solution from the residual solids. Such conditions determine the degree of cellulolytic enhancement obtainable through the combination of liquor and a GH61 polypeptide during hydrolysis of a cellulosic substrate by a cellulase preparation. The liquor can be separated from the treated material using a method standard in the art, such as filtration, sedimentation, or centrifugation.</p>
      <p id="p-00257-en" num="0255">In one aspect, an effective amount of the liquor to cellulose is about 10<sup>−6 </sup>to about 10 g per g of cellulose, e.g., about 10<sup>−6 </sup>to about 7.5 g, about 10<sup>−6 </sup>to about 5, about 10<sup>−6 </sup>to about 2.5 g, about 10<sup>−6 </sup>to about 1 g, about 10<sup>−5 </sup>to about 1 g, about 10<sup>−5 </sup>to about 10<sup>−1 </sup>g, about 10<sup>−4 </sup>to about 10<sup>−1 </sup>g, about 10<sup>−3 </sup>to about 10<sup>−1 </sup>g, or about 10<sup>−3 </sup>to about 10<sup>−2 </sup>g per g of cellulose.</p>
      <p id="p-00258-en" num="0256">The invention can also be described by the following embodiments:</p>
      <p id="p-00259-en" num="0000">1. An isolated polypeptide having cellulolytic enhancing activity, selected from the group consisting of:</p>
      <p id="p-00260-en" num="0257">(a) a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 2; at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 4; at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 6; at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 8;</p>
      <p id="p-00261-en" num="0258">(b) a polypeptide encoded by a polynucleotide that hybridizes under medium-high stringency conditions, high stringency conditions, or very high stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 (ii) the cDNA sequence thereof, or (iii) the full-length complement of (i) or (ii);</p>
      <p id="p-00262-en" num="0259">(c) a polypeptide encoded by a polynucleotide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1; or the cDNA sequence thereof; at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 3; or the cDNA sequence thereof; at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 5; or the cDNA sequence thereof; at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 7; or the cDNA sequence thereof;</p>
      <p id="p-00263-en" num="0260">(d) a variant of the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 comprising a substitution, deletion, and/or insertion at one or more positions; and</p>
      <p id="p-00264-en" num="0261">(e) a fragment of the polypeptide of (a), (b), (c), or (d) that has cellulolytic enhancing activity.</p>
      <p id="p-00265-en" num="0000">2. The polypeptide of embodiment 1, comprising or consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8. <br /> 3. The polypeptide of embodiment 2, wherein the mature polypeptide is amino acids 20 to 319 of SEQ ID NO: 2; amino acids 24 to 347 of SEQ ID NO: 4; amino acids 20 to 240 of SEQ ID NO: 6 or amino acids 19 to 355 of SEQ ID NO: 8. <br /> 4. The polypeptide of embodiment 1, which is a variant of the mature polypeptide of SEQ ID NO: 2, the mature polypeptide of SEQ ID NO: 4, the mature polypeptide of SEQ ID NO: 6 or the mature polypeptide of SEQ ID NO: 8 comprising or containing a substitution, deletion, and/or insertion at one or more (e.g. several) positions. <br /> 5. The polypeptide of embodiment 1, which is a fragment of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, wherein the fragment has cellulolytic enhancing activity. <br /> 6. A composition comprising the polypeptide of any of embodiments 1-5. <br /> 7. The composition of embodiment 6, comprising one or more additional enzymes selected among a cellulase, a hemicellulase, an expansin, an esterase, a laccase, a ligninolytic enzyme, a pectinase, a peroxidase, a protease, and a swollenin. <br /> 8. Use of a composition of embodiment 6 or 7 for degrading cellulose. <br /> 9. The use of embodiment 8, wherein the cellulose is part of a lignocellulosic material. <br /> 10. The use of embodiment 9, wherein the lignocellulosic material is selected among herbaceous material, agricultural residue, such as corn stover, corn fibre, orange peel, rice or wheat straw, switch grass or bagasse, forestry residue, municipal solid waste, waste paper, and pulp and paper mill residue. <br /> 11. The use of embodiment 10, where the lignocellulosic material is pretreated. <br /> 12. The use of embodiment 11, wherein the pretreated lignocellulosic material is pretreated corn stove or Kraft pulp. <br /> 13. The use of embodiment 8-11, wherein the polypeptide is used in the presence of a dioxy compound, a bicylic compound, a heterocyclic compound, a nitrogen-containing compound, a quinone compound, a sulfur-containing compound, or a liquor obtained from a pretreated cellulosic material such as pretreated corn stover (PCS). <br /> 14. The use of any of the embodiments 8 to 13, in a process for producing a fermented product. <br /> 15. The use of embodiment 14, where the fermented product is ethanol. <br /> 16. An isolated polynucleotide encoding the polypeptide of any of embodiments 1-5. <br /> 17. A nucleic acid construct or expression vector comprising the polynucleotide of embodiment 16 operably linked to one or more control sequences that direct the production of the polypeptide in an expression host. <br /> 18. A recombinant host cell comprising the polynucleotide of embodiment 16 operably linked to one or more control sequences that direct the production of the polypeptide. <br /> 19. The recombinant host cell of embodiment 18, selected among bacteria, fungal, mammalian, insect or plant cells. <br /> 20. The recombinant host cell of embodiment 19, wherein the host cell is a fungal cell selected among <i>Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes</i>, or <i>Trichoderma </i>cell. <br /> 21. The recombinant host cell of embodiment 20, selected among <i>Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Bjerkandera adusta, Ceriporiopsis aneirina, Ceriporiopsis caregiea, Ceriporiopsis gilvescens, Ceriporiopsis pannocinta, Ceriporiopsis rivulosa, Ceriporiopsis subrufa, Ceriporiopsis subvermispora, Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Coprinus cinereus, Coriolus hirsutus, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola insolens, Humicola lanuginosa, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium purpurogenum, Phanerochaete chrysosporium, Phlebia radiata, Pleurotus eryngii, Thielavia terrestris, Trametes villosa, Trametes versicolor, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei</i>, or <i>Trichoderma viride </i>cell. <br /> 22. A method of producing the polypeptide of any of embodiments 1-5, comprising: </p>
      <p id="p-00266-en" num="0262">(a) cultivating a cell, which in its wild-type form produces the polypeptide, under conditions conducive for production of the polypeptide; and</p>
      <p id="p-00267-en" num="0263">(b) recovering the polypeptide.</p>
      <p id="p-00268-en" num="0000">23. A method of producing a polypeptide having cellulytic enhancing activity, comprising:</p>
      <p id="p-00269-en" num="0264">(a) cultivating the host cell of embodiment 18-21, under conditions conducive for production of the polypeptide; and</p>
      <p id="p-00270-en" num="0265">(b) recovering the polypeptide.</p>
      <p id="p-00271-en" num="0266">The present invention is further described by the following examples that should not be construed as limiting the scope of the invention.</p>
      <heading id="h-00016-en" level="1">EXAMPLES</heading>
      <heading id="h-00017-en" level="1">Strains</heading>
      <p id="p-00272-en" num="0267">A strain of the fungus <i>Lentinus similis </i>was used as donor organism for this project. The strain was isolated for an environmental sample isolated in China. <i>Aspergillus oryzae </i>MT3568 strain was used for expression of the <i>L. similis </i>genes encoding the polypeptide having cellulolytic enhancing activity activity. <i>A. oryzae </i>MT3568 is an amdS (acetamidase) disrupted gene derivative of <i>Aspergillus oryzae </i>JaL355 (WO 2002/40694) in which pyrG auxotrophy was restored by disrupting the <i>A. oryzae </i>acetamidase (amdS) gene.</p>
      <heading id="h-00018-en" level="2">Media and Solutions</heading>
      <p id="p-00273-en" num="0268">YP+2% glucose medium was composed of 1% yeast extract, 2% peptone and 2% glucose.</p>
      <p id="p-00274-en" num="0269">YP+2% maltodextrin medium was composed of 1% yeast extract, 2% peptone and 2% maltodextrin.</p>
      <p id="p-00275-en" num="0270">PDA agar plates were composed of potato infusion (potato infusion was made by boiling 300 g of sliced (washed but unpeeled) potatoes in water for 30 minutes and then decanting or straining the broth through cheesecloth. Distilled water was then added until the total volume of the suspension was one liter, followed by 20 g of dextrose and 20 g of agar powder. The medium was sterilized by autoclaving at 15 psi for 15 minutes (Bacteriological Analytical Manual, 8th Edition, Revision A, 1998).</p>
      <p id="p-00276-en" num="0271">LB plates were composed of 10 g of Bacto-Tryptone, 5 g of yeast extract, 10 g of sodium chloride, 15 g of Bacto-agar, and deionized water to 1 liter.</p>
      <p id="p-00277-en" num="0272">LB medium was composed of 10 g of Bacto-Tryptone, 5 g of yeast extract, and 10 g of sodium chloride, and deionized water to 1 liter.</p>
      <p id="p-00278-en" num="0273">COVE sucrose plates were composed of 342 g of sucrose, 20 g of agar powder, 20 ml of COVE salt solution, and deionized water to 1 liter. The medium was sterilized by autoclaving at 15 psi for 15 minutes (Bacteriological Analytical Manual, 8th Edition, Revision A, 1998). The medium was cooled to 60° C. and 10 mM acetamide, 15 mM CsCl, Triton X-100 (50 μl/500 ml) were added.</p>
      <p id="p-00279-en" num="0274">COVE salt solution was composed of 26 g of MgSO<sub>4</sub>.7H<sub>2</sub>O, 26 g of KCL, 26 g of KH<sub>2</sub>PO<sub>4</sub>, 50 ml of COVE trace metal solution, and deionized water to 1 liter.</p>
      <p id="p-00280-en" num="0275">COVE trace metal solution was composed of 0.04 g of Na<sub>2</sub>B<sub>4</sub>O<sub>7</sub>.10H<sub>2</sub>O, 0.4 g of CuSO<sub>4</sub>.5H<sub>2</sub>O, 1.2 g of FeSO<sub>4</sub>.7H<sub>2</sub>O, 0.7 g of MnSO<sub>4</sub>.H<sub>2</sub>O, 0.8 g of Na<sub>2</sub>MoO<sub>4</sub>.2H<sub>2</sub>O, 10 g of ZnSO<sub>4</sub>.7H<sub>2</sub>O, and deionized water to 1 liter.</p>
      <heading id="h-00019-en" level="1">Example 1</heading>
      <heading id="h-00020-en" level="1">
        <i>Lentinus similis </i>Genomic DNA Extraction</heading>
      <p id="p-00281-en" num="0276">To generate genomic DNA, <i>Lentinus similis </i>was propagated on PDA agar plates by growing at 26° C. for 7 days. Spores harvested from the PDA plates were used to inoculate 25 ml of YP+2% glucose medium in a baffled shake flask and incubated at 26° C. for 4 days with agitation at 200 rpm.</p>
      <p id="p-00282-en" num="0277">Genomic DNA was isolated according to a modified DNeasy Plant Maxi kit protocol (Qiagen Danmark, Copenhagen, Denmark). The fungal material from the above culture was harvested by centrifugation at 14,000×g for 2 minutes. The supernatant was removed and the 0.5 g of the pellet was frozen in liquid nitrogen with quartz sand and grinded to a fine powder in a pre-chilled mortar. The powder was transferred to a 15 ml centrifuge tube and added 5 ml buffer AP1 (preheated to 65° C.) and 10 μl RNase A stock solution (100 mg/ml) followed by vigorous vortexing. After incubation for 10 minutes at 65° C. with regular inverting of the tube, 1.8 ml buffer AP2 was added to the lysate by gentle mixing followed by incubation on ice for 10 min. The lysate was then centrifugated at 3000×g for 5 minutes at room temperature and the supernatant was decanted into a QIAshredder maxi spin column placed in a 50 ml collection tube. This was followed by centrifugation at 3000×g for 5 minutes at room temperature. The flow-through was transferred into a new 50 ml tube and added 1.5 volumes of buffer AP3/E followed by vortexing. 15 ml of the sample was transferred into a DNeasy Maxi spin column placed in a 50 ml collection tube and centrifuged at 3000×g for 5 minutes at room temperature. The flow-through was discarded and 12 ml buffer AW was added to the DNeasy Maxi spin column placed in a 50 ml collection tube and centrifuged at 3000×g for 10 minutes at room temperature. After discarding the flow-through, centrifugation was repeated to dispose of the remaining alcohol. The DNeasy Maxi spin column was transferred to a new 50 ml tube and 0.5 ml buffer AE (preheated to 70° C.) was added. After incubation for 5 minutes at room temperature, the sample was eluded by centrifugation at 3000×g for 5 minutes at room temperature. Elution was repeated with an additional 0.5 ml buffer AE and the eluates were combined. The concentration of the harvested DNA was measured by a UV spectrophotometer at 260 nm.</p>
      <heading id="h-00021-en" level="1">Example 2</heading>
      <heading id="h-00022-en" level="1">Source of DNA Sequence Information for <i>Lentinus similis </i></heading>
      <p id="p-00283-en" num="0278">2 ug of chromosomal DNA isolated as described in example 1, was subjected to partial shotgun genome sequencing, a service that is commercially available at FASTERIS SA, Switzerland. The genome sequence was analyzed for protein sequences that have GH61 glycosyl hydrolase domains (according to the CAZY definition above). Four genes and corresponding protein sequence was identified from the sequence information (SEQ ID NO: 1, 3, 5, and 7) and selected for further investigation</p>
      <heading id="h-00023-en" level="1">Example 3</heading>
      <heading id="h-00024-en" level="1">Construction of <i>Aspergillus oryzae </i>Expression Vectors Containing <i>Lentinus similis </i>Genomic Sequences Each Encoding a Family GH61 Polypeptide</heading>
      <p id="p-00284-en" num="0279">Two synthetic oligonucleotide primers were designed for each of the four GH61 identified GH61 genes to PCR amplify the <i>Lentinus similis </i>GH61 genes from the genomic DNA prepared in Example 1. An IN-FUSION™ Cloning Kit (BD Biosciences, Palo Alto, Calif., USA) was used to clone the fragment directly into the expression vector pDau109 (WO 2005/042735).</p>
      <p id="p-00285-en" num="0280">Following primers were used for the PCR amplifications:</p>
      <p id="p-00286-en" num="0000">
        <tables id="tables-00001-en" num="00001">
          <table frame="none" colsep="0" rowsep="0" tabstyle="monospace">
            <tgroup cols="1" colsep="0" rowsep="0" align="left">
              <colspec colname="1" colwidth="217pt" align="left" />
              <tbody valign="top">
                <row>
                  <entry>For amplification of the coding sequence</entry>
                </row>
                <row>
                  <entry>of SEQ ID NO: 1:</entry>
                </row>
                <row>
                  <entry>Primer F-1:</entry>
                </row>
                <row>
                  <entry>(SEQ ID NO. 9)</entry>
                </row>
                <row>
                  <entry>5′-<u>acacaactggggatcc</u>accATGTTGTCTCTCTCCGTCGCTA-3′</entry>
                </row>
                <row>
                  <entry />
                </row>
                <row>
                  <entry>Primer R-1:</entry>
                </row>
                <row>
                  <entry>(SEQ ID NO: 10)</entry>
                </row>
                <row>
                  <entry>5′-<u>ccctctagatctcgag</u>CCTTGCGGCAATCGGGATACT-3′</entry>
                </row>
                <row>
                  <entry />
                </row>
                <row>
                  <entry>For amplification of the coding sequence</entry>
                </row>
                <row>
                  <entry>of SEQ ID NO. 3:</entry>
                </row>
                <row>
                  <entry>Primer F-3:</entry>
                </row>
                <row>
                  <entry>(SEQ ID NO: 11)</entry>
                </row>
                <row>
                  <entry>5′-<u>acacaactggggatcc</u>accATGAAGACTTTCTCTGCTATCGTT</entry>
                </row>
                <row>
                  <entry />
                </row>
                <row>
                  <entry>CTCT-3′</entry>
                </row>
                <row>
                  <entry />
                </row>
                <row>
                  <entry>Primer R-3:</entry>
                </row>
                <row>
                  <entry>(SEQ ID NO. 12)</entry>
                </row>
                <row>
                  <entry>5′-<u>ccctctagatctcgag</u>GAGGGGAGAGGGGAAGA-3′</entry>
                </row>
                <row>
                  <entry />
                </row>
                <row>
                  <entry>For amplification of the coding sequence</entry>
                </row>
                <row>
                  <entry>of SEQ ID NO: 5:</entry>
                </row>
                <row>
                  <entry>Primer F-5:</entry>
                </row>
                <row>
                  <entry>(SEQ ID NO. 13)</entry>
                </row>
                <row>
                  <entry>5′-<u>acacaactggggatcc</u>accATGAAAACTTGGGCCGTGCTA-3′</entry>
                </row>
                <row>
                  <entry />
                </row>
                <row>
                  <entry>Primer R-5:</entry>
                </row>
                <row>
                  <entry>(SEQ ID NO. 14)</entry>
                </row>
                <row>
                  <entry>5′-<u>ccctctagatctcgag</u>ATCGCTGGCTCAGGGCAAT-3′ </entry>
                </row>
                <row>
                  <entry />
                </row>
                <row>
                  <entry>For amplification of the coding sequence </entry>
                </row>
                <row>
                  <entry>of SEQ ID NO. 7:</entry>
                </row>
                <row>
                  <entry>Primer F-7:</entry>
                </row>
                <row>
                  <entry>(SEQ ID NO. 15)</entry>
                </row>
                <row>
                  <entry>5′-<u>acacaactggggatc</u>caccATGTTTGGCGCACTCTTGGTCT-3′ </entry>
                </row>
                <row>
                  <entry />
                </row>
                <row>
                  <entry>Primer R-7:</entry>
                </row>
                <row>
                  <entry>(SEQ ID NO. 16)</entry>
                </row>
                <row>
                  <entry>5′-<u>ccctctagatctcgag</u>CTGTCGCACTTCTCTGCTGCA-3′ </entry>
                </row>
              </tbody>
            </tgroup>
          </table>
        </tables> Capital letters represent gene sequences. The underlined sequences are homologous to the insertion sites of pDau109. </p>
      <p id="p-00287-en" num="0281">An MJ Research PTC-200 DNA engine (MJ Research Inc., Waltham, Mass., USA) was used to perform the PCR reactions. A Phusion® High-Fidelity PCR Kit (Finnzymes Oy, Espoo, Finland) was used for the PCR amplification. The PCR reactions were composed of 5 μl of 5×HF buffer (Finnzymes Oy, Espoo, Finland), 0.5 μl of dNTPs (10 mM), 0.5 μl of Phusion® DNA polymerase (0.2 units/μl) (Finnzymes Oy, Espoo, Finland), 5 μM of each primer, 0.5 μl of <i>L. similis </i>genomic DNA (100 ng/μl), and 16.5 μl of deionized water in a total volume of 25 μl. The PCR conditions were 1 cycle at 95° C. for 2 minutes. 35 cycles each at 98° C. for 10 seconds, 60° C. for 30 seconds, and 72° C. for 2 minutes; and 1 cycle at 72° C. for 10 minutes. The samples were then held at 12° C. until removed from the PCR machine.</p>
      <p id="p-00288-en" num="0282">The reaction products were isolated by 1.0% agarose gel electrophoresis using 40 mM Tris base, 20 mM sodium acetate, 1 mM disodium EDTA (TAE) buffer where product bands of approximately 1200-1400 bp were excised from the gel and purified using an illustra GFX® PCR DNA and Gel Band Purification Kit (GE Healthcare Life Sciences, Brondby, Denmark) according to the manufacturer's instructions. The fragments were then cloned into Bam HI and Xho I digested pDau109 using an IN-FUSION™ Cloning Kit resulting in the plasmids pGH61-1, pGH61-3, pGH61-5 and pGH61-7 respectively. Cloning of the genes into Bam HI-Xho I digested pDau109 resulted in the transcription of the Lentinis <i>similis </i>GH61 genes under the control of a NA2-tpi double promoter. NA2-tpi is a modified promoter from the gene encoding the <i>Aspergillus niger </i>neutral alpha-amylase in which the untranslated leader has been replaced by an untranslated leader from the gene encoding the <i>Aspergillus nidulans </i>triose phosphate isomerase.</p>
      <p id="p-00289-en" num="0283">The cloning protocol was performed according to the IN-FUSION™ Cloning Kit instructions generating four GH61 constructs. The treated plasmids and inserts were transformed into One Shot® TOP10F′ Chemically Competent <i>E. coli </i>cells (Invitrogen, Carlsbad, Calif., USA) according to the manufacturer's protocol and plated onto LB plates supplemented with 0.1 mg of ampicillin per ml. After incubating at 37° C. overnight, colonies were seen growing under selection on the LB ampicillin plates. Colonies of each transformation were cultivated in LB medium supplemented with 0.1 mg of ampicillin per ml and plasmids were isolated with a QlAprep Spin Miniprep Kit (QIAGEN Inc., Valencia, Calif., USA) according to the manufacturer's protocol.</p>
      <p id="p-00290-en" num="0284">Isolated plasmids were sequenced with vector primers and gene specific primers in order to determine representative plasmid expression clones that were free of PCR errors, and plasmids without errors were selected for expression of the polypeptides.</p>
      <heading id="h-00025-en" level="1">Example 4</heading>
      <heading id="h-00026-en" level="1">Characterization of the <i>Lentinus similis </i>Genomic Sequences Encoding Four GH61</heading>
      <p id="p-00291-en" num="0285">Polypeptides</p>
      <p id="p-00292-en" num="0286">DNA sequencing of the <i>Lentinus similis </i>GH61 genomic clones were performed with an Applied Biosystems Model 3700 Automated DNA Sequencer using version 3.1 BIG-DYE™ terminator chemistry (Applied Biosystems, Inc., Foster City, Calif., USA) and primer walking strategy. Nucleotide sequence data were scrutinized for quality and all sequences were compared to each other with assistance of PHRED/PHRAP software (University of Washington, Seattle, Wash., USA). The sequences obtained were identical to the sequence from the genome sequencing (see example 2).</p>
      <p id="p-00293-en" num="0287">The nucleotide sequence and deduced amino acid sequence of the <i>Lentinus similis </i>GH61-1 gene are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively, the nucleotide sequence and deduced amino acid sequence of the <i>Lentinus similis </i>GH61-3 gene are shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively, the nucleotide sequence and deduced amino acid sequence of the <i>Lentinus similis </i>GH61-5 gene are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively, and the nucleotide sequence and deduced amino acid sequence of the <i>Lentinus similis </i>GH61-7 gene are shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.</p>
      <p id="p-00294-en" num="0288">The coding sequence of GH61-1 is 960 by including the stop codon and is interrupted by introns of 55 bp (nucleotides 279 to 333), 55 bp (nucleotides 444 to 499), 49 bp (nucleotides 510 to 558), 52 bp (nucleotides 706 to 757), 54 bp (nucleotides 811 to 864), and 59 bp (nucleotides 930 to 988). The encoded predicted protein is 319 amino acids. Using the SignalP program (Nielsen et al., 1997<i>, Protein Engineering </i>10: 1-6), a signal peptide of 19 residues was predicted. The predicted mature protein contains 300 amino acids.</p>
      <p id="p-00295-en" num="0289">The coding sequence of GH61-3 is 1144 bp including the stop codon and is interrupted by introns of 53 bp (nucleotides 240 to 292), 74 bp (nucleotides 454 to 527), and 64 bp (nucleotides 676 to 739). The encoded predicted protein is 347 amino acids. Using the SignalP program (Nielsen et al., 1997<i>, Protein Engineering </i>10: 1-6), a signal peptide of 23 residues was predicted. The predicted mature protein contains 324 amino acids.</p>
      <p id="p-00296-en" num="0290">The coding sequence of GH61-5 is 723 bp including the stop codon and is interrupted by introns of 63 bp (nucleotides 351 to 413), 60 bp (nucleotides 480 to 539), 74 bp (nucleotides 715 to 788), 68 bp (nucleotides 808 to 875), 66 bp (nucleotides 931 to 996), 66 bp (nucleotides 1133 to 1198), 52 bp (nucleotides 1240 to 1291), 58 bp (nucleotides 1371 to 1428), and 75 bp (nucleotides 1486 to 1560). The encoded predicted protein is 240 amino acids. Using the SignalP program (Nielsen et al., 1997, <i>Protein Engineering </i>10: 1-6), a signal peptide of 19 residues was predicted. The predicted mature protein contains 221 amino acids.</p>
      <p id="p-00297-en" num="0291">The coding sequence of GH61-7 is 1068 bp including the stop codon and is interrupted by introns of 54 bp (nucleotides 225 to 278), 55 bp (nucleotides 440 to 494), 64 bp (nucleotides 714 to 777), and 66 bp (nucleotides 937 to 1002). The encoded predicted protein is 355 amino acids. Using the SignalP program (Nielsen et al., 1997, <i>Protein Engineering </i>10: 1-6), a signal peptide of 18 residues was predicted. The predicted mature protein contains 337 amino acids.</p>
      <heading id="h-00027-en" level="1">Example 5</heading>
      <heading id="h-00028-en" level="1">Expression of <i>Lentinus similis </i>GH61 Genes in <i>Aspergillus oryzae </i>MT3568</heading>
      <p id="p-00298-en" num="0292">Error-free clones comprising the GH61-1 gene of SEQ ID NO: 1, the GH61-3 gene of SEQ ID NO: 3, the GH61-5 gene of SEQ ID NO: 5 and the GH61-7 gene of SEQ ID NO: 7 were selected for further work. Plasmid DNA was then isolated as described in Example 3. The purified plasmid DNA was transformed into <i>Aspergillus oryzae </i>MT3568. <i>A. oryzae </i>MT3568 protoplasts were prepared according to the method of European Patent EP0238023, pages 14-15. Transformants resulting from the transformation of <i>A. oryzae </i>MT3568 with the four plasmids were inoculated into separate wells of a 96 microtiter deep well plate (Nunc NS, Roskilde, Denmark) with each well containing 750 μl of YP+2% glucose medium or 750 μl YP+2% maltodextrin medium. The plate was covered with Nunc pre scored vinyl sealing tape (Thermo Fisher Scientific, Roskilde, Denmark) and incubated at 26° C. stationary for 4 days. The transformants were also streaked onto COVE sucrose (+10 mM acetamide+15 mM CsCl+TRITON® X-100 (50 μl/500 ml)). The plates were incubated at 37° C. and this selection procedure was repeated in order to stabilize the transformants.</p>
      <p id="p-00299-en" num="0293">Several <i>Aspergillus oryzae </i>transformants produced the recombinant GH61-1 polypeptide of SEQ ID NO: 2, the GH61-3 polypeptide of SEQ ID NO: 4, the GH61-5 polypeptide of SEQ ID NO: 6 or the GH61-7 polypeptide of SEQ ID NO: 8 as judged by SDS PAGE analysis.</p>
      <heading id="h-00029-en" level="1">Example 6</heading>
      <heading id="h-00030-en" level="1">Purification of the GH61-1 Polypeptide of SEQ ID NO: 2</heading>
      <p id="p-00300-en" num="0294">An <i>Aspergillus oryzae </i>transformant producing the recombinant GH61-1 polypeptide of SEQ ID NO: 2, from Example 5, was inoculated in 2 L YP+2% glucose medium and incubated at 37° C. for 2 days. Mycelium was removed by filtration and the broth collected for purification of protein.</p>
      <p id="p-00301-en" num="0295">To approximately 1844 ml broth was added ammonium sulphate to 1.0M and the pH was adjusted to 7.5. The mixture aw filtered through a Whatmann GF/D filter and loaded on a 50 mm diameter 167 ml Butyl-ToyoPearl 650 (Tosoh Biosciences, Stuttgart, Germany) column that previously had been equilibrated in buffer A (25 mM Tris.HCl, 1.0 M ammonium sulphate, pH 7.5). The column was washed in buffer A and eluted with a gradient of 0-100% buffer B (25 mM Tris.HCl pH 7.5) followed by a gradient 0-20% Ethanol, and collection of fractions of the eluate.</p>
      <p id="p-00302-en" num="0296">Samples of all collected fractions were run on a SDS-PAGE gel (1 mm, 4-20% Tris-glycine, Invitrogen), according to the manufacturers instructions, and the factions containing a band of the extected size was combined and concentrated to a volume of approximately 7 ml using a Vivaspin 20, centrifugal concentrator (Vivaproducts, Littleton, USA).</p>
      <p id="p-00303-en" num="0297">The concentrate was diluted with Milli-Q water to a conductivity of below 5, (approximately 90 ml) and loaded on a SOURCE 15S column (GE Healthcare) previously equilibrated in 50 mM NaOAc, pH 5.0. The column was washed in same buffer and eluted with a gradient of 0-50% 50 mM NaOAc+1 M NaCl, pH 5.0 over 60 minutes with a flow of 3 ml/min and collection of fractions of 6 ml. A sample of the wash solution and of all fractions was applied to a SDS-PAGE gel (1 mm, 4-20% tris-glycine, Invitrogen) according to the manufacturer's instructions and all fractions with a band in the expected size were pooled. The volume was reduced to 2 ml using a Vivaspin 20 centrifugal concentrator (Vivaproducts, Littleton, USA) according to the manufacturers instructions, and diluted to approximately 5.5 ml in 20 mM MES+125 M NaCl, pH 6.0 and applied to size exclusion chromatography using a HiLoad 26/60 Superdex 75 column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).</p>
      <p id="p-00304-en" num="0298">The column was eluted in 20 mM MES+125 mM NaCl, pH 6.0 and a flow of 3 ml/min with collection of fractions of 6 ml. A sample of each fraction was analysed by SDS-PAGE gel electrophorese, as described above. Several fractions contained a band of the expected size appx 30 kDa and these fractions were pooled. Other fractions contained a band of approximately double size and also these fractions were pooled.</p>
      <p id="p-00305-en" num="0299">The two combined preparations were further analysed by protein sequencing by the EDMAN method and it was confirmed that both preparations contained a polypeptide having the sequence of SEQ ID NO: 2.</p>
      <heading id="h-00031-en" level="1">Example 7</heading>
      <heading id="h-00032-en" level="1">Purification of the GH61-3 Polypeptide of SEQ ID NO: 4, the GH61-5 Polypeptide of SEQ ID NO: 6 and GH61-7 Polypeptide of SEQ ID NO: 8</heading>
      <p id="p-00306-en" num="0300">
        <i>Aspergillus oryzae </i>transformants producing the recombinant GH61-3 polypeptide of SEQ ID NO: 4, the recombinant GH61-5 polypeptide of SEQ ID NO: 6 and the recombinant GH61-7 polypeptide of SEQ ID NO: 8, all from Example 5, were grown essentially as described in Example 6 and the recombinant polypeptides were purified essentially as described in Example 6.</p>
      <heading id="h-00033-en" level="1">Example 8</heading>
      <heading id="h-00034-en" level="1">Determining Activity of the Purified Polypeptides</heading>
      <p id="p-00307-en" num="0301">The activity of the purified polypeptides was determined using the methylene blue assay that has been found to correspond to cellulolytic enhancing activity. The activity assay was performed in 96-wells plate using a microplate reader from Spectra Max M2 (Molecular Devices, Sunnyvale, Calif., USA). Temperature of the microplate reader was set at 37° C. The reaction mixture consisted of 50 mM MOPS/NaOH, 20 μM CuSO<sub>4</sub>, 0.1 mM methylene blue, 4 mM pyrogallol pH 7.0 buffer and samples of the purified polypeptides of Example 6 and 7. The reaction was initiated by addition of pyrogallol and monitored at 400 nm. For controls, all the components were included except the GH61 polypeptide. After a 15 minute reaction, absorbance readings at 400 nm were made and corrected by deducting the absorbance of the controls.</p>
      <p id="p-00308-en" num="0302">Following activities were measured:</p>
      <p id="p-00309-en" num="0000">
        <tables id="tables-00002-en" num="00002">
          <table frame="none" colsep="0" rowsep="0">
            <tgroup cols="3" colsep="0" rowsep="0" align="left">
              <colspec colname="offset" colwidth="28pt" align="left" />
              <colspec colname="1" colwidth="35pt" align="left" />
              <colspec colname="2" colwidth="154pt" align="center" />
              <thead>
                <row>
                  <entry />
                  <entry namest="offset" nameend="2" align="center" rowsep="1" />
                </row>
                <row>
                  <entry />
                  <entry>Sample</entry>
                  <entry>Activity (ΔOD400/min/μmol)</entry>
                </row>
                <row>
                  <entry />
                  <entry namest="offset" nameend="2" align="center" rowsep="1" />
                </row>
              </thead>
              <tbody valign="top">
                <row>
                  <entry />
                </row>
              </tbody>
            </tgroup>
            <tgroup cols="3" colsep="0" rowsep="0" align="left">
              <colspec colname="offset" colwidth="28pt" align="left" />
              <colspec colname="1" colwidth="35pt" align="left" />
              <colspec colname="2" colwidth="154pt" align="char" char="." />
              <tbody valign="top">
                <row>
                  <entry />
                  <entry>GH61-1</entry>
                  <entry>14.19</entry>
                </row>
                <row>
                  <entry />
                  <entry>GH61-3</entry>
                  <entry>26.70</entry>
                </row>
                <row>
                  <entry />
                  <entry>GH61-5</entry>
                  <entry>2.58</entry>
                </row>
                <row>
                  <entry />
                  <entry namest="offset" nameend="2" align="center" rowsep="1" />
                </row>
              </tbody>
            </tgroup>
          </table>
        </tables>
      </p>
      <heading id="h-00035-en" level="1">Example 9</heading>
      <heading id="h-00036-en" level="1">Preparation of <i>Humicola insolens </i>Cellobiose Dehydrogenase Polypeptide</heading>
      <p id="p-00310-en" num="0303">
        <i>Humicola insolens </i>cellobiose dehydrogenase (CDH) polypeptide was recombinantly prepared in <i>Aspergillus oryzae </i>essentially as described in Xu et al (Enzyme and Microbial Technology 28 (2001) 744-753.</p>
      <p id="p-00311-en" num="0304">The recombinantly produced <i>H. insolens </i>CDH polypeptide was first concentrated from 60 ml to 7 ml, by ultrafiltration using a 10 kDa membrane (VIVASPIN®, GE Healthcare, Piscataway, N.J., USA), buffer exchanged into 20 mM Tris-HCl plus 150 mM NaCl pH 8.0, and then purified using a 320 ml SUPERDEX® 75 column (GE Healthcare, Piscataway, N.J., USA) equilibrated with 20 mM Tris-HCl plus 150 mM NaCl pH 8.0 at a flow rate of 1 ml per minute. Fractions of 5 ml were collected and pooled based on SDS-PAGE.</p>
      <p id="p-00312-en" num="0305">Protein concentration was determined using total amino acid quantification or a Microplate BCA™ Protein Assay Kit (Thermo Fisher Scientific Inc., Rockford, Ill., USA) in which bovine serum albumin was used as a protein standard.</p>
      <heading id="h-00037-en" level="1">Example 10</heading>
      <heading id="h-00038-en" level="1">Protocols for Modifying Cellulosic Materials with GH61 Polypeptides</heading>
      <p id="p-00313-en" num="0306">The modification of cellulosic materials with GH61 polypeptides was performed according to the protocols described below.</p>
      <p id="p-00314-en" num="0307">Microcrystalline cellulose (AVICEL® PH101; Sigma-Aldrich Chemical Co., St. Louis, Mo., USA) and C10<sub>2</sub>-bleached <i>Eucalyptus </i>kraft pulp (washed and oven-dried with −55% moisture and −20% hemicellulose) were used as sources of the cellulosic material.</p>
      <p id="p-00315-en" num="0308">The modification of the cellulosics was conducted using autoclaved 1.7 ml plastic capped microcentrifuge tubes according to the following protocol. First the cellulosics were suspended in a total reaction volume of 1 ml with 20 mg of AVICEL® or bleached pulp per ml of 50 mM sodium acetate pH 5.0 buffer for two days. After decanting the solution, the hydrated and buffer-exchanged cellulosics were resuspended a total reaction volume of 1 ml of 50 mM sodium acetate pH 5.0 buffer with and without <i>L. similis </i>GH61 polypeptide (pre-incubated with equal molar copper (II) sulphate (CuSO<sub>4</sub>) at 4° C. for 1 day) at 1 mg per g cellulosic, either alone, or with 1 mM of manganese (II) sulfate (MnSO<sub>4</sub>) and 5 mM ascorbate, or with 1 mg of CDH per g cellulosic. The tubes were capped, mixed thoroughly, and incubated at 50° C. for 94 hours in an Isotemp Plus incubator (Thermo Fisher Scientific Inc., Waltham, Mass., USA). All experiments were performed in duplicate.</p>
      <heading id="h-00039-en" level="1">Example 11</heading>
      <heading id="h-00040-en" level="1">Methods of Evaluating the Modification of Cellulosic Materials by Treatment with GH61 Polypeptides—Bicinchoninic Acid (BCA) Assay</heading>
      <p id="p-00316-en" num="0309">The modification of cellulosic materials by treatment with GH61 polypeptides was evaluated according to the procedures described below.</p>
      <p id="p-00317-en" num="0310">For the 1 ml protocol described in Example 10, cellulosic samples treated with the GH61 polypeptide were cooled to 23° C. and centrifuged at 20000×g for 2 minutes. The resulting AVICEL® pellets or pulp fibers were analyzed for aldosyl or aldehyde group (reducing end) content as described below. The pellets or fibers were washed and decanted four times in −1.6 ml of water purified by a Milli-Q device (Millipore, Billerica Mass., USA) followed by centrifugation. Then the washed pellets or fibers were mixed with 0.95 ml of BCA (bicinchoninic acid) Protein Assay working solution (prepared by mixing 50:1 BCA Reagents A and B) (Thermo Fisher Scientific Inc., Waltham, Mass., USA) or 0.95 ml of BCA solution plus 22 μl of water, and incubated at 50° C. for 1 hour then 23° C. for 16 hours in an Isotemp Plus incubator. Mixtures of 45 μl of 0 to 5 mM glucose standards and 0.955 ml of the BCA Protein Assay working solution were incubated in parallel. After incubation, the mixtures were cooled to 23° C., centrifuged at 20000×g, and the supernatants were separated from the insoluble materials. The supernatants were again centrifuged at 20000×g to sediment any residual material. One-hundred μl volume of the supernatants was transferred to a 96-well microplate, and the absorbance at 562 nm was measured using a SPECTROMAX® 340PC 384 plate reader (Molecular Devices, Inc., Sunnyvale, Calif., USA) to quantify the aldosyl/aldehyde-reacted BCA assay product. When the absorbance was 1.5 or higher, the supernatant was diluted with non-reacted but incubated BCA Protein Assay working solution control, so that the absorbance was close to 1. Data from glucose standards were used to quantify equivalent aldosyl/aldehyde groups.</p>
      <heading id="h-00041-en" level="1">Example 12</heading>
      <heading id="h-00042-en" level="1">Effect of <i>Lentinus similis </i>GH61-3 Polypeptide Treatment of Microcrystalline Cellulose: Aldosyl/Aldehyde Group Detection by the BCA Assay</heading>
      <p id="p-00318-en" num="0311">The effect of <i>L. similis </i>GH61-3 polypeptide on the modification of AVICEL® was determined by the BCA assay using the same experimental conditions and procedures described in Example 11.</p>
      <p id="p-00319-en" num="0312">After incubation with <i>L. similis </i>GH61-3 polypeptide, ascorbate, MnSO<sub>4</sub>, and buffer, 0.66±0.06 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L reacted AVICEL®. After incubation with ascorbate, MnSO<sub>4</sub>, and buffer, 0.58±0.04 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L reacted AVICEL®. After incubation with buffer, 0.48±0.01 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L reacted AVICEL®. Thus, the GH61 polypeptide treatment resulted in approximately 15±12% more aldosyl/aldehyde groups compared to the GH61-3 polypeptide-free control. The GH61-3 polypeptide treatment and GH61-3 polypeptide-free control resulted in 36±12 and 19±8% more aldosyl/aldehyde groups in AVICEL®, respectively, compared to buffer-incubated AVICEL®.</p>
      <p id="p-00320-en" num="0313">After incubation with <i>L. similis </i>GH61-3 polypeptide, <i>H. insolens </i>CDH polypeptide, and buffer, 0.53±0.02 mM glucose-equivalent aldosyl/aldehyde groups were measured from reacted 20 g/L AVICEL®. After incubation with <i>H. insolens </i>CDH polypeptide and buffer, 0.62±0.04 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L AVICEL®. After incubation with buffer, 0.48±0.01 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L AVICEL®. Thus, the GH61-3 polypeptide treatment resulted in 15±7% less aldosyl/aldehyde groups compared to the GH61-3 polypeptide-free control, and 10±5% more aldosyl/aldehyde groups compared to buffer-incubated AVICEL®.</p>
      <heading id="h-00043-en" level="1">Example 13</heading>
      <heading id="h-00044-en" level="1">Effect of <i>Lentinus similis </i>GH61-3 Polypeptide Treatment of Bleached <i>Eucalyptus </i>Kraft Pulp: Aldosyl/Aldehyde Group Detection by the BCA Assay</heading>
      <p id="p-00321-en" num="0314">The effect of <i>L. similis </i>GH61-3 polypeptide on the modification of bleached kraft pulp was determined by the BCA assay using the same experimental conditions and procedures described in Example 11.</p>
      <p id="p-00322-en" num="0315">After incubation with <i>L. similis </i>GH61-3 polypeptide, ascorbate, MnSO<sub>4</sub>, and buffer, 0.240±0.005 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L reacted pulp. After incubation with ascorbate, MnSO<sub>4</sub>, and buffer, 0.229±0.008 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L reacted pulp. After incubation with buffer, 0.059±0.000 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L reacted pulp. Thus, the GH61 polypeptide treatment resulted in approximately 4.9±4.2% more aldosyl/aldehyde groups compared to the GH61-3 polypeptide-free control. The GH61-3 polypeptide treatment and GH61-3 polypeptide-free control resulted in 304±8 and 286±14% more aldosyl/aldehyde groups in pulp, respectively, compared to buffer-incubated pulp.</p>
      <p id="p-00323-en" num="0316">After incubation of with <i>L. similis </i>GH61-3 polypeptide, <i>H. insolens </i>CDH polypeptide, and buffer, 0.248±0.011 mM glucose-equivalent aldosyl/aldehyde groups were measured from reacted 20 g/L pulp. After incubation of with <i>H. insolens </i>CDH polypeptide and buffer, 0.148±0.006 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L reacted pulp. After incubation with buffer, 0.059±0.000 mM glucose-equivalent aldosyl/aldehyde groups were measured from 20 g/L reacted pulp. Thus, the GH61-3 polypeptide treatment resulted in 68±9% more aldosyl/aldehyde groups compared to the GH61-3 polypeptide-free control, and 319±19% more aldosyl/aldehyde groups compared to buffer-incubated pulp.</p>
    </detailed-desc>
  </description>
  <claims id="claims_eng" lang="eng" format="original" date-changed="20150903">
    <claim num="1" id="clm-00001-en" independent="true">
      <claim-text>
        <b>1</b>. An isolated polypeptide having cellulolytic enhancing activity, selected from the group consisting of:
<claim-text>(a) a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 2; at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 4; at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 6; at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 8;</claim-text><claim-text>(b) a polypeptide encoded by a polynucleotide that hybridizes under medium-high stringency conditions, high stringency conditions, or very high stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 (ii) the cDNA sequence thereof, or (iii) the full-length complement of (i) or (ii);</claim-text><claim-text>(c) a polypeptide encoded by a polynucleotide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1; or the cDNA sequence thereof; at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 3; or the cDNA sequence thereof; at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 5; or the cDNA sequence thereof; at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 7; or the cDNA sequence thereof;</claim-text><claim-text>(d) a variant of the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 comprising a substitution, deletion, and/or insertion at one or more positions; and</claim-text><claim-text>(e) a fragment of the polypeptide of (a), (b), (c), or (d) that has cellulolytic enhancing activity.</claim-text></claim-text>
    </claim>
    <claim num="2" id="clm-00002-en">
      <claim-text>
        <b>2</b>. The polypeptide of <claim-ref idref="clm-00001-en">claim 1</claim-ref>, comprising or consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.</claim-text>
    </claim>
    <claim num="3" id="clm-00003-en">
      <claim-text>
        <b>3</b>. The polypeptide of <claim-ref idref="clm-00002-en">claim 2</claim-ref>, wherein the mature polypeptide is amino acids 20 to 319 of SEQ ID NO: 2; amino acids 24 to 347 of SEQ ID NO: 4; amino acids 20 to 240 of SEQ ID NO: 6 or amino acids 19 to 355 of SEQ ID NO: 8.</claim-text>
    </claim>
    <claim num="4" id="clm-00004-en">
      <claim-text>
        <b>4</b>. The polypeptide of <claim-ref idref="clm-00001-en">claim 1</claim-ref>, which is a variant of the mature polypeptide of SEQ ID NO: 2, the mature polypeptide of SEQ ID NO: 4, the mature polypeptide of SEQ ID NO: 6 or the mature polypeptide of SEQ ID NO: 8 comprising or containing a substitution, deletion, and/or insertion at one or more (e.g. several) positions.</claim-text>
    </claim>
    <claim num="5" id="clm-00005-en">
      <claim-text>
        <b>5</b>. The polypeptide of <claim-ref idref="clm-00001-en">claim 1</claim-ref>, which is a fragment of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, wherein the fragment has cellulolytic enhancing activity.</claim-text>
    </claim>
    <claim num="6" id="clm-00006-en">
      <claim-text>
        <b>6</b>. A composition comprising the polypeptide of <claim-ref idref="clm-00001-en">claim 1</claim-ref>.</claim-text>
    </claim>
    <claim num="7" id="clm-00007-en">
      <claim-text>
        <b>7</b>. The composition of <claim-ref idref="clm-00006-en">claim 6</claim-ref>, comprising one or more additional enzymes selected among a cellulase, a hemicellulase, an expansin, an esterase, a laccase, a ligninolytic enzyme, a pectinase, a peroxidase, a protease, and a swollenin.</claim-text>
    </claim>
    <claim num="8" id="clm-00008-en" independent="true">
      <claim-text>
        <b>8</b>. (canceled)</claim-text>
    </claim>
    <claim num="9" id="clm-00009-en" independent="true">
      <claim-text>
        <b>9</b>. (canceled)</claim-text>
    </claim>
    <claim num="10" id="clm-00010-en">
      <claim-text>
        <b>10</b>. An isolated polynucleotide encoding the polypeptide of <claim-ref idref="clm-00001-en">claim 1</claim-ref>.</claim-text>
    </claim>
    <claim num="11" id="clm-00011-en">
      <claim-text>
        <b>11</b>. A nucleic acid construct or expression vector comprising the polynucleotide of <claim-ref idref="clm-00010-en">claim 10</claim-ref> operably linked to one or more control sequences that direct the production of the polypeptide in an expression host.</claim-text>
    </claim>
    <claim num="12" id="clm-00012-en">
      <claim-text>
        <b>12</b>. A recombinant host cell comprising the polynucleotide of <claim-ref idref="clm-00010-en">claim 10</claim-ref> operably linked to one or more control sequences that direct the production of the polypeptide.</claim-text>
    </claim>
    <claim num="13" id="clm-00013-en">
      <claim-text>
        <b>13</b>. A method of producing the polypeptide of <claim-ref idref="clm-00001-en">claim 1</claim-ref>, comprising:
<claim-text>(a) cultivating a cell, which in its wild-type form produces the polypeptide, under conditions conducive for production of the polypeptide; and</claim-text><claim-text>(b) recovering the polypeptide.</claim-text></claim-text>
    </claim>
    <claim num="14" id="clm-00014-en">
      <claim-text>
        <b>14</b>. A method of producing a polypeptide having cellulytic enhancing activity, comprising:
<claim-text>(a) cultivating the host cell of <claim-ref idref="clm-00012-en">claim 12</claim-ref> under conditions conducive for production of the polypeptide; and</claim-text><claim-text>(b) recovering the polypeptide.</claim-text></claim-text>
    </claim>
  </claims>
  <image file="US20150247137A1.PDF" type="pdf" size="3163753" pages="38" />
</lexisnexis-patent-document>